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MECHANISM OF TRANSFORMATION AND THERAPEUTIC TARGETS FOR 
HEMATOLOGICAL NEOPLASMS HARBORING ONCOGENIC KIT MUTATION 
 
Gain-of-function mutations in the KIT receptor tyrosine kinase have been 
associated with highly malignant human neoplasms. In particular, an acquired somatic 
mutation at codon 816 in the second catalytic domain of KIT involving an aspartic acid to 
valine substitution is found in patients with systemic mastocytosis (SM) and acute 
myeloid leukemia (AML). The presence of this mutation in SM and AML is associated 
with poor prognosis and overall survival. This mutation changes the conformation of the 
KIT receptor resulting in altered substrate recognition and constitutive tyrosine 
autophosphorylation leading to constitutive ligand independent growth. As there are 
currently no efficacious therapeutic agents against this mutation, this study sought to 
define novel therapeutic targets that contribute to aberrant signaling downstream from 
KITD816V that promote transformation of primary hematopoietic stem/progenitor cells 
in diseases such as AML and SM. This study shows that oncogenic KITD814V (murine 
homolog) induced myeloproliferative neoplasms (MPN) occurs in the absence of ligand 
stimulation, and that intracellular tyrosines are important for KITD814V-induced MPN. 
Among the seven intracellular tyrosines examined, tyrosine 719 alone has a unique role 
in regulating KITD814V-induced proliferation and survival.  Residue tyrosine 719 is vital 
for activation of the regulatory subunit of phosphatidylinositol 3-kinase (PI3K), p85, 
downstream from KITD814V. Downstream effectors of the PI3K signaling pathway, in 
vi 
 
particular p21 activated kinase (Pak) and its upstream effectors including guanine 
exchange factors (GEF) Vav1 and the Rho family of GTPases (Rac) exhibit constitutive 
activation and contribute to gain-of-function mutant-mediated transformation. Treatment 
of leukemic cells bearing KITD814V with an allosteric inhibitor of Pak or its genetic 
inactivation results in growth repression due to enhanced apoptosis. To assess the role of 
Rac GEFs in KITD814V induced transformation, EHop-016, an inhibitor of Rac, was 
used to specifically target Vav1, and found to be a potent inhibitor of human and murine 
leukemic cell growth. In vivo, the inhibition of Vav or Rac or Pak delayed the onset of 
MPN and rescued the associated pathology in mice. These studies provide insight on 
mechanisms and potential novel therapeutic targets for hematological malignancies 
harboring an oncogenic KIT mutation. 
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CHAPTER ONE 
INTRODUCTION 
 
Core Binding Factor-Acute Myeloid Leukemia 
The core binding factor (CBF) is a heterodimeric transcription factor containing 
transcriptional subunits of enhancers and promoters that play an integral role in 
hematopoiesis and leukemogeneis (2). RUNX1 was the first CBF gene to be isolated and 
is known also as AML1, CBF2, and PEBP2B. RUNX1 is part of the Runt-related 
transcription factors (RUNXs), and plays a specific role in regulating early embryonic 
hematopoiesis and specifying hematopoietic stem cells (HSC) (3, 4). The importance of 
RUNX1 can be appreciated as RUNX1 knockout mice do not develop fetal liver 
hematopoiesis, and are embryonic lethal by E11.5-E12.5 due to hemorrhaging in the 
central nervous system (5). Similar effects are also seen when another CBF subunit, 
CBF, is knocked out during development (6). Furthermore, RUNX1 plays not only a 
role in fetal hematopoiesis, but is critical for adult hematopoiesis and HSC self-renewal. 
RUNX1 forms a heterodimeric complex with CBF that binds to DNA at the Runt 
Homolog Domain (RHD) located in the N-terminus of RUNX1. Complexing with CBF 
facilitates RUNX1 binding to DNA and stabilizes the complex from proteolysis. The 
RUNX1/ CBF complex of transcription factors recruits additional cofactors like p900 
and CREB-binding protein, all of which is controlled by RUNX1. These cofactors help in 
acetylating histones and unraveling condense DNA making promoter regions more 
accessible for transcription. The CBF complex binds the DNA consensus sequence of 
PyGPyGGTPy (Py is a pyrimidine base) (7). The CBF complex regulates transcription of 
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a number of crucial hematopoietic-specific genes, including interleukin 3 (IL-3), 
macrophage colony-stimulating factor receptor (M-CSFR), neutrophil elastase, 
myeloperoxidase and granzyme B (8-11).  
Another transcription family of interest is the protein family Eight-Twenty One 
(ETO) that comprises of ETO (MTG8), ETO2 (MTG16 or MTGR2) and MTGR1 (12-
14). The ETO family members suppress transcription by recruiting histone deacteylases 
and associated transcription repression complexes such as N-CoR, SMRT, or mSin3A.  
In 20% of acute myeloid leukemias (AML) a chromosome rearrangement of t(8;21) is 
found that results in a fusion of the gene RUNX1 on chromosome 21q22 with ETO on 
chromosome 8q22 (Figure 1.1) (15). As a consequence of this translocation, a fusion 
protein is generated which contains the N terminal and RHD of the RUNX1 protein and 
nearly the complete ETO protein (AML1-ETO) (16, 17). This chimeric fusion product, 
AML1-ETO, retains the ability to bind to CBF and to interact with the DNA consensus 
sequence (7). However, the fusion results in a protein in which ETO actively represses 
RUNX1-mediated transcription by recruitment of co-repressors N-CoR, SMRT, and 
mSin3A (18-20). The importance of the CBF complex is further demonstrated by the 
chromosomal rearrangement inv(16)(p13;q22) resulting in a fusion product CBF-
MYH11. This fusion protein is present in about 12% of AMLs and 40% of M2-AMLs 
(21) (Figure 1.1).  Like AML1-ETO, CBF-MYH11 leads to a disruption of transcription 
of definitive hematopoiesis and loss of differentiation.   
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Association of KIT with Core Binding Factor chromosome translocations 
Many studies of adults and children show that de novo AML associated with 
t(8;21) or inv(16) alone have a favorable response to treatment with high complete 
response rates and overall survival (22-24). However, a cooperative model of AML has 
been substantiated in which more than one acquired mutation is present in most AMLs, a 
mutation that blocks differentiation and an additional mutation that drives proliferation 
(Table 1.1).  Recent data and reviews support modifications to the Knudson’s “two-hit” 
Figure 1.1. Prevalence of chromosomal rearrangements and their associated 
fusion products in AML patients. 
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hypothesis, in which involvement of genes regulating epigenetics are critical for 
leukemogeneis (25-28). 
 
Table 1.1. Multiple hits associated with leukemogenesis.   
 
A multiple hit model of leukemogenesis has been proposed to result from the cooperation 
between multiple classes of mutations. These mutation can be divided into classes that 
provide a proliferative advantage, can block differentiation potential of cells, and can 
affect epigenetic regulation. 
 
Proliferation Advantage Block Differentiation Epigenetic Regulators 
BCR-ABL CBFβ–MYH11 TEL–AML1 
N-Ras AML1–ETO ASXL1 
K-Ras TEL–AML1 DNMT3A 
KIT (exon 8) PML–RARα EZH2 
KIT (Asp 816) NUP98–HOXA9  
Flt3 (ITD) PU.1  
Flt3 (Asp 835) C/CEPα  
PTPN11 AML1  
NF1 AML1–AMP19  
 
Clinical reports strongly suggest cooperation between activating KIT mutations 
and core binding factor TFs in a subset of AMLs. Approximately 12.8 to 46.1% of adults 
with core binding factor leukemias express activating KIT mutations (29-31). Acquired 
mutations in KIT have been associated with higher incidence of elevated white blood cell 
(WBC) counts, greater relapse incidence and worse overall survival in AML patients 
expressing t(8;21) or inv(16) (Figure 1.2). KIT mutations have been observed in CBF-
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AMLs and have been observed in multiple clinical studies involving diverse ethnic 
groups and countries, including studies conducted in Japan, Italy and other parts of 
Europe and US (29, 31). Importantly, KIT mutations are not observed in many other 
subsets of AML (32, 33). These studies strongly support the notion of cooperativity 
between KIT mutations and CBF translocations in a subset of AML, and suggest that KIT 
mutations may be a poor prognostic indicator on outcome of CBF-AML in both adult and 
pediatric patients. However, these studies do not directly prove the notion that KIT 
mutations cooperate with CBF transcription factors (TFs) in CBF-AML. One of the 
specific aims of my thesis was to investigate the cooperation between KITD816V 
mutation and CBF TFs in AML. 
 
 
Figure 1.2. Kaplan-Meier survival analysis of AML (AML1-ETO) patients with or 
without KITD816V mutations. 
 
(A) This study shows 4-year overall survival and (B) disease-free survival of AML1-ETO 
patients with KITD816V mutation (red line) or without a KITD816V mutation (blue 
line). The differences are statistically significant. Figure adapted from Shimada et al.  
(34). 
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Systemic mastocytosis 
Mastocytosis is a heterogenous disorder characterized by an abnormal 
accumulation of mast cells (MC) in tissues. The disease was first described in 1869 as 
brown lesions that would welt following scratching (35). The disease was described in 
1878 as urticaria pigmentosa and in the following year the mast cell was discovered by 
Paul Ehrlich (36). The association between an accumulation of MC in the dermis and 
urticaria pigmentosa was made by Unna in 1887 (37). Depending on the affected organs, 
mastocytosis can be divided into cutaneous mastocytosis, in which MC aggregates 
become deposited in the dermis, or systemic mastocytosis (SM) in which MCs become 
deposited in the bone marrow (BM) as well as extramedullary tissues like spleen, 
gastrointestinal tract, lymph node, and liver (38). The World Health Organization 
proposed major and minor criteria for the diagnosis and classification of mastocytosis 
(Table 1.2), and has described several subvariants: cutaneous mastocytosis, indolent 
systemic mastocytosis (ISM), aggressive SM (ASM), SM associated with a clonal 
hematopoietic non-MC disorder (SM-AHNMD), Mast cell leukemia (MCL), and MC 
sarcoma (MCS) (38-40).  
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Table 1.2. World Health Organization Diagnostic Criteria for Systemic 
Mastocytosis. 
 
 
Although little is known about the pathogenic factors that contribute to 
mastocytosis, molecular determination of the mutation status of KIT has represented a 
major step in understanding the molecular mechanisms of this disease. Somatic point 
mutations in KIT at codon 816 (D816V > 95%; D816H, D816Y and others <5%) are 
detected in >90% of patients with SM (41-45). These findings suggest that the KIT 
mutation status is important for clinical diagnosis, and could represent a hallmark of 
pathogenesis in SM patients.  
The KITD816V mutation is prevalent in both aggressive SM (SM-AHNMD, 
ASM, and MCL) and non-aggressive SM (ISM) (38, 39, 46, 47). The expression of 
KITD816V alone is insufficient to manifest all forms of mastocytosis in vivo (48). It is 
likely that additional factors may also contribute to aggressive subtypes of SM. To this 
Criteria 
Major criterion 
1) Multifocal, dense infiltrates of MC ( 15 MC in aggregates) in bone marrow 
and/or other extracutaneous organ(s) 
Minor criteria 
1) 25% of MC in bone marrow or other extracutaneous organ(s) show an 
immature or abnormal morphology (typically spindle-shaped) 
2) Activating KIT mutation at codon 816 in BM, blood, or other extracutaneous 
organ(s) 
3) MC in BM express CD117 and CD2 and/or CD25 in addition to normal MC 
markers 
4) Total serum trypase 20 ng/mL (unless patient has an associated clonal 
myeloid disorder) 
 A diagnosis of systemic mastocytosis requires the fulfillment of the major 
criterion or at least 3 minor criteria 
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end, recent studies have identified genes that are frequently mutated in advanced SM 
including TET2, DNMT3A, ASXL1, EZH2, RUNX1, CBL, and IDH1/IDH2 (49-51). TET2 
is a tumor suppressor that functions in DNA demethylation (52, 53). Loss of function 
mutations of Tet2 have been documented in acute and chronic myeloid malignancies (50, 
54). Furthermore, a significant growth advantage is observed in primary murine bone 
marrow-derived MCs expressing KITD816V that are Tet2 deficient relative to wild type 
cells (55). These findings suggest that additional genetic aberrations to KITD816V may 
contribute to a more aggressive form of SM.  
 
Structure and function of receptor tyrosine kinase KIT 
Receptor tyrosine kinases (RTKs) are widely expressed transmembrane proteins 
that have critical function in several developmental processes including regulation of cell 
survival, motility, growth and differentiation (56). Many of these functions are mediated 
in hematopoietic stem and progenitor cells (HSC/Ps) through the RTK KIT.  The proto-
oncogene KIT belongs to the RTK class III family, other members include platelet-
derived growth factor receptor (PDGFR), macrophage colony stimulating factor receptor 
(M-CSFR), and Fms-like tyrosine kinase (FLT3) (57-59). The class III family members 
are membrane bound glycoproteins that are characterized by five immunoglobulin-like 
(Ig) domains on the extracellular region, a single transmembrane spanning domain and 
two intracellular kinase domains connected by a kinase insert domain (60). This family of 
RTKs has a pivotal role in normal hematopoiesis, and many of its family members have 
been associated with hematological malignancies.  
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RTK KIT signaling is important in erythropoiesis, lymphopoiesis, mast cell 
development, megakaryopoiesis, gametogenesis and melanogenesis. KIT activation is 
driven by binding of the ligand stem cell factor (SCF), which exists as a non-covalent 
dimer.  In the murine system, SCF is encoded by the steel (Sl) locus while KIT is 
encoded by dominant white spotting (W) locus. Loss of function mutations of KIT in 
humans leads in piebaldism, a congenital hypopigmentation disease characterized by 
hypopigmented patches on the midforehead, chest, and extremities due to melanocyte 
defects (61, 62). In mice, the loss of function mutations in the loci of SCF or KIT affects 
development of hematopoietic cells, melanocytes, germ cells, and survival (63-65). 
Transgenic mice with knock out of the KIT gene or of its ligand, SCF gene, are 
embryonic lethal by day 16 of gestation due to severe anemia (66). 
Activation of KIT is driven by SCF binding to the three distal Ig-like domains on 
the extracellular portion of the receptor. This binding of SCF brings two KIT monomers 
together and facilitates interactions of the fourth and fifth Ig-like domain causing the 
formation of a rigid KIT homodimer (67). The cytoplasmic domain of KIT involves a 
kinase insert that splits the kinase domain into an adenosine triphosphate (ATP)-binding 
domain as well as a phosphotyrosine activation domain. KIT also has a juxtamembrane 
domain (JM) that inhibits receptor dimerization and enzyme activity by maintaining 
control of the -helix and activation loop, in the cytoplasmic domain. After dimerization, 
transphosphorylation of two tyrosine residues, tyrosine 568 and tyrosine 570, in the 
autoinhibitory domain causes a conformational change that keeps the JM domain from 
immobilizing the activation loop (68). The activation loops are then converted from a 
compact conformation to an open active conformation allowing for transphosphorylation 
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of the activation loop tyrosine 823, thus stabilizing activity for binding of the enzyme 
(69).  
Upon non-covalent binding of SCF binding, the KIT homodimer undergoes 
tyrosine autophosphorylation at specific tyrosine residues in the cytoplasmic domain. The 
phosphorylated tyrosine residues act as high-affinity-binding site for protein substrates to 
dock.  Recruitment of specific src homology 2 domains (SH2) containing proteins leads 
to KIT-mediated signal transduction. The activated KIT can then bind an array of 
intracellular signaling molecules including Src family kinases at tyrosine 567 and 569, 
Grb2 at tyrosine 702, p85 subunit of class IA of phosphatidylinositol 3-kinase (PI3K) at 
tyrosine 719, SHP2 phosphatase, phospholipase C at tyrosine 728, Ras-GAP at tyrosine 
745, and Grb7 at tyrosine 934, thereby initiating a signaling cascade resulting in various 
cellular changes (70-72). Although these interactions have been well characterized in WT 
KIT, little is known concerning individual contribution of these pathways in oncogenic 
KIT transformation. An additional specific aim of my project was to understand the 
individual contribution of these pathways on oncogenic KIT induced transformation. 
 
KIT mutations in human neoplasms 
A number of tyrosine kinase receptors that function in hematopoiesis have been 
found to have crucial roles in leukemogenesis. To this end, activating mutations of KIT 
have been reported in AML, gastrointestinal stromal tumors (GIST), melanomas, NK/T 
cell lymphomas, SM, and germ line cell tumors (41, 73). Two distinct types of mutations 
provoke oncogenic activation of KIT, one which involves the JM domain and the other 
involves the phosphotransferase domain in normal hematopoietic stem cells and cell lines 
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(Figure 1.3) (74, 75). Mutations of the JM domain lead to constitutive dimerization of 
KIT in the extracellular domain leading to constitutive activation (e.g. KITV560G, 
associated with (GISTs) in the absence of ligand stimulation. In contrast, KIT mutations 
of the activation loop (e.g. KITD816V, associated with AML and SM), do not result in 
dimerization, but are found rather to result in receptor self-association in the cytoplasmic 
domain (76). The mechanism of self-association in the absence of dimerization is not 
well understood, including whether the extracellular domain is necessary for KITD816V 
function, constitutive activation and capabilities for signal protein association, in a ligand 
independent manner (77).  Transforming potential in the absence of the extracellular 
domain strongly suggests that the self-association observed in KITD816V is conferred 
upon the receptor via the D816V mutation in the cytoplasmic domain, rather than 
influences from the extracellular domain. Although a significant amount is known in our 
structural understanding of the KITD816V receptor, there is still relatively little 
understood about the oncogenic signaling pathways and regulation that contribute to the 
receptor’s transforming ability. 
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KIT-targeted therapies 
Small molecule therapy has been shown to be beneficial for many neoplastic 
disorders including imatinib (STI-571, Gleevec), which is a clinically effective protein 
receptor tyrosine kinase inhibitor. Not only has imatinib been effective in treating chronic 
myelogenous leukemia with the t(9;22) (BCR-ABL) translocation, but this molecule has 
also been efficacious against activating mutations in KIT in the JM domain that have 
been associated with GISTs and melanomas (78).  Imatinib functions by targeting the 
inactive conformation of KIT and binds sites in the ATP-binding domain thereby 
inhibiting its kinase activity (79, 80). These observations suggest that imatinib would be 
Figure 1.3. Schematic representation KIT and KIT mutations associated with 
AML, SM and other human malignancies. 
Adapted from Heinrich et al. (1) 
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beneficial for other neoplasms involving activating mutations of KIT like SM or AML. 
However, mutations within the activation domain of KIT, such as those found in the 
KITD816V version of the receptor, are highly resistant to such therapy (81). Modeling 
has demonstrated that mutations near sites of drug-protein interaction induce 
conformational changes in the activation loop that reduce the binding affinity of KIT for 
imatinib, thereby reducing drug efficacy (82). Imatinib is potentially promising for 
effective treatment against GISTs and melanomas with JM mutations or in ASM and 
MCL patients who are negative for KITD816V mutation. However, it is proven to be an 
ineffective treatment for neoplasms harboring the KITD816V mutation (1, 83).   
Other small molecule inhibitors that have been found to be clinically active by US 
Food and Drug Administration include sunitinib for treatment against KIT in GISTs (84). 
Sunitinib inhibits KIT mutations and shows inhibitory effects against VEGF making it 
more effective than imatinib, likewise dasatinib is a Src/Abl kinase inhibitor that is 300-
fold more potent than imatinib (85, 86). Although both of these inhibitors have 
significant activity against wild type KIT, they are both ineffective treatments against 
neoplasms bearing KITD816V, and have shown little to variable efficacy in clinic (87). 
Several drugs aimed to target the KIT receptor have been largely ineffective at 
treating patients bearing the KITD816V mutation. Several other inhibitors of KITD816V 
are currently under clinical investigation that exhibit adequate efficacy and safety profiles 
to be considered for further development as therapeutic in combination with standard 
therapy for AML. For instance midostaurin (PKC412), a broad-spectrum inhibitor that 
targets FLT3, KIT, PDGFR, and c-FMS, is presently recruiting AML patients bearing a 
KITD816V mutation for a Phase I/II trial (88). 
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An approach to bypass KITD816V resistance to inhibitors targeting receptor 
tyrosine kinases would be to target downstream effectors of KITD816V signaling. 
Therefore, downstream effectors of oncogenic KIT need to be evaluated as potential 
novel therapeutic targets for patients with AML and SM bearing a KITD816V mutation. 
An additional specific aim of my thesis was to identify novel therapeutic targets that may 
be involved in the transforming potential of the KITD816V mutation downstream from 
oncogenic KIT. 
 
Altered signaling via the KITD816V receptor 
Mutation of aspartic acid to valine in exon 17 of the activation loop of KIT, 
KITD816V (human) and KITD814V (murine), leads to alterations in the recognition of 
downstream substrates (89). The KITD816V mutation results in constitutive activation of 
the receptor and leads to aberrant signaling regulation and promiscuous signaling. 
Alterations in signaling include the activation of signal transducer and activator of 
transcription 3 (STAT3) as well as degradation of KIT-signal inhibitory molecules, such 
as SHP-1 (90).  Identifying molecular and regulatory changes in the activating KIT 
mutation that contributes to its oncogenic transformation may allow for alternative 
therapeutic targets. In the murine model, one strategic approach is to identify and directly 
target KITD814V effector molecules that contribute to the transformation ability of 
oncogenic KITD814V-bearing cells. Functional and pharmacologic studies using cell line 
models and an inhibitor of PI3K, wortmannin, have indicated that the lipid kinase PI3K 
may have a role in contributing to the oncogenic potential of KITD814V (91). Utilizing 
an in vivo model of myeloproliferative neoplasms (MPN) our lab has demonstrated that 
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deficiency of p85 regulatory subunit of PI3K rescues the transformation by KITD814V. 
Unfortunately, although useful in in vitro systems, the PI3K inhibitor wortmannin is less 
than ideal in an in vivo setting due to its broad spectrum, nonspecific inhibition, and 
extreme toxicity (92).  PI3K is a key regulator in many different physiological events 
including cell proliferation, differentiation, apoptosis, cytoskeletal organization and 
membrane trafficking (93-95). Thus targeting specific downstream effectors of PI3K may 
provide a better therapeutic alternative.  Lines of evidence indicate that PI3K activity is 
necessary for several Rac-regulated cellular functions, and that products of PI3K activate 
guanine exchange factors (GEFs) for Rac including Vav1 (Figure 1.4.A), which promote 
the conversion of inactive guanosine diphosphate (GDP)-bound Rac to active guanosine 
triphosphate (GTP)-bound form (Figure 1.4.B) (72, 96, 97). An additional specific aim of 
my thesis was to assess the role of Vav1 and Rac in KITD816V induced transformation 
and their potential as therapeutic targets. 
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Figure 1.4. Schematic of (A) guanine nucleotide exchange factor (GEF) Vav1 and 
(B) Rac GTPase activation loop. 
 
Regulation of guanine exchange factor Vav1 
Dysregulation of Vav1 has been associated with transformation, in which 
mutations including substitution of tyrosine to phenylalanine at residue 174 of Vav1 or 
the amino terminal deletion of the calponin-homology (CH) domain and acidic (AC) 
motif of Vav1 induces transformation (Figure 1.4.A) (98, 99). Vav1 has a role in 
transformation, it is unclear what the biological effects of hyperactivation of Vav1 by 
oncogenic mutation in a receptor tyrosine kinase, such as KIT are. The effects in primary 
hematopoietic cells have yet to be addressed. Vav1, as well as family members Vav2 and 
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Vav3, consist of several conserved domains, including a dbl homology (DH) region, a 
pleckstrin homology (PH) domain, a SH2 and two Src-homology3 (SH3) domains, and 
exhibit GEF function that activate specific members of the Rho GTPase family (Figure 
1.4.A) (100).  Vav1’s catalytic activity is tightly regulated by phosphorylation of tyrosine 
174 in the AC domain, relieving auto-inhibitory intra-molecular interactions involving 
the N-terminal of Vav1 that block access to the DH domain, thereby activating GEF 
activity (101). The PH domain also regulates GEF activity through the binding of PI3K 
products (Figure 1.4.A). Of the known Rac GEFs, Vav proteins are the only ones known 
to have three Src-homology domains that are able to recruit adaptor molecules 
independent of its GEF activity.  
 
 Regulation of Rac GTPases  
The GEF catalytic activity of Vav1 is relatively specific to the Rac subfamily of 
Rho GTPases (Rac1 and Rac2). The Rac subfamily of Rho GTPases have been 
implicated in a wide range of cellular functions, including structure of actin cytoskeleton, 
transcriptional and translational activity, cell survival, cell cycle entry as well as being 
implemented in transformation (102, 103).  Dysregulation of the Rac subfamily has been 
associated with a number of human cancers including, leukemias, lymphomas, gastric 
tumors, breast cancer, and head and neck squamous cell carcinomas (104, 105). These 
proteins act as molecular switches that cycle between an inactive GDP-bound 
conformation and an active GTP-bound conformation (Figure 1.4.B).  The Rac GTPase 
subfamily includes three structurally related proteins, Rac1 and Rac3 are ubiquitously 
expressed, while the third protein Rac2 is restricted to the hematopoietic compartment. 
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Studies involving Rac1 and/or Rac2 deficient mice have shown that the Rac proteins are 
essential in multiple hematopoietic lineages; the deficiency of both Rac1 and Rac2 
demonstrates the most profound effects (106). 
 
Summary and Significance 
It has been hypothesized that KIT activation loop mutants, including KITD816V 
(human) and its murine homologue KITD814V, alter the specificity of KIT substrate 
recognition and utilization (89). As a result signals emanating from the oncogenic KIT 
(KITD816V) can be promiscuous in nature and induce aberrant signals not normally 
regulated by wild type KIT, including the activation of STAT3 and the degradation of 
KIT-signaling inhibitory molecules, such as SHP-1 (89, 90, 107). Given the fact imatinib 
and other second generation tyrosine kinase inhibitors, such as sunitnib and dasatinib, 
have shown poor efficacy against this receptor in clinical trials, an alternative therapeutic 
approach to directly targeting KIT could involve targeting KIT effector molecules that 
contribute to the transformation of KITD816V-bearing cells. Previous studies by our lab 
and others have shown that the lipid kinase, PI3K, maybe necessary and sufficient in the 
transforming ability of D816V (murine D814V) (91, 97, 108).  Although the use of 
wortmannin as a PI3K inhibitor is useful in experimental in vitro systems, this inhibitor is 
non-specific, and is associated with high cytotoxicity in vivo (92). Multiple lines of 
evidence demonstrate that several Rac-regulated cellular functions depend on PI3K 
activity, and that products of PI3K activate GEFs for Rac including Vav, which promote 
the conversion of inactive Rac-GDP to active Rac-GTP (96, 109). Importantly among the 
various Vav and Rac family members Vav1 and Rac2 are expressed specifically in 
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hematopoietic cells and deficiency of these molecules perturbs specialized functions in 
mature leukocytes without significantly affecting the growth of hematopoietic 
progenitors. We hypothesized that the Vav/Rac pathway may be a useful pathway to 
target disease involving KITD814V mutation.   
The main objective of this study was to understand the molecular mechanisms 
contributing to KITD816V-induced transformation in order to determine molecular 
targets and potential molecular-based therapeutic options to treat KITD816V-positive 
AML and SM patients. Our studies specifically address the following aims: 
SPECIFIC AIM 1: We hypothesized that endogenous ligand binding is not 
necessary for KITD814V-induced MPN. We utilized a chimeric receptor lacking the 
extracellular region of the KIT receptor to determine if the KITD814V mutation can 
induce ligand-independent growth in vitro and MPN in vivo.  
SPECIFIC AIM 2: We hypothesized that the tyrosine residues within the JM 
and/or the kinase insert region of KITD814V play an essential role in ligand independent 
growth in vitro and transformation in vivo. We dissected the role of tyrosines in the JM 
and kinase insert region of KITD814V in transformation and activation and binding of 
downstream effectors such as PI3K, AKT, ERK, and STAT5. 
SPECIFIC AIM 3: We hypothesized that the hematopoietic specific guanine 
exchange factor Vav1 contributes to transformation by KITD814V. We determined the 
extent to which deficiency of Vav1 in hematopoietic stem/progenitor cells contributes to 
the MPN phenotype by KITD814V using a genetic approach. 
SPECIFIC AIM 4: We hypothesized that the Rho family GTPases Rac1 and 
Rac2, downstream effectors of Vav1, contribute to KITD814V induced transformation. 
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We determined the extent to which Rac1 and/or Rac2 GTPases contribute to KITD814V 
induced transformation in vitro and MPN in vivo. 
SPECIFIC AIM 5: We hypothesized that AML1-ETO and KITD814V cooperate 
in vitro. We determined the contribution of co-expressing AML1-ETO and KITD814V in 
vitro on growth and activation of downstream effectors. 
SPECIFIC AIM 6: We established murine models to study primary human AML 
and SM patient samples or patient-derived cells to study AML and SML in vivo both 
locally and systemically as models for therapeutic regimes. 
 
Our overall proposed molecular mechanism for KITD814V activation is 
generalized by the schematic diagram in Figure 1.5.  
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Figure 1.5. Schematic of proposed KITD814V molecular mechanisms described and 
identified in these studies. 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
A. Materials 
1. Plasmids 
cDNA for WT KIT, KITD814V, AML1-ETO, RACN17, and CHR receptor 
constructs were expressed into an improved murine stem cell virus (MSCV)-based  
bicistronic retroviral vector, MIEG3, upstream of the internal ribosome entry site (IRES) 
and the enhanced green fluorescent protein (EGFP) or human CD4 (hCD4) gene.  
 
2. Primers 
Standard polymerase chain reaction (PCR) reactions for genotyping transgenic animals 
were performed using oligonucleotides synthesized by Invitrogen. 
 
Table 2.1. Genotyping primers 
Gene Forward (5′-3′) Reverse (5′-3′) Null (5’-3’) 
Rac1 flox 
5’-TCC AAT CTG 
TGC TGC CCA TC- 
3’ 
5’-CAG AGC TCG 
AAT CCA GAA ACT 
AGT A- 3’ 
5’-GAT GCT TCT 
AGG GGT GAG CC- 
3’ 
Rac2 null 
5´-GAC GCA TGC 
TCC ACC CCC T-3’ 
5´-CAC ACA CTT GAT 
GGC CTG CAT-3’ 
5´-TGC CAA GTT 
CTA ATT CCA TCA 
GAA GC-3’ 
Mx-Cre 
5´-CAA CCT CAG 
TAC CAA GCC 
AAG-3´ 
5´-CTT CCC AGG 
GAG AAT CAA AGC- 
3´ 
5´-CGC ATA ACC 
AGT GAA ACA 
GCA T- 3´ 
KITD814
V 
5´-GAA AGA GCG 
GCA GAC AAG AG-
3’ 
5´-TGA GGT CTC TCA 
GCT CAG GTG-3’ 
5´-AGA GGC CAC 
TTG TGT AGC GC-
3’ 
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Table 2.2. Sequencing Primers for Confirmation of Mutagenesis of Internal 
Tyrosine Residues 
 
CHR primers Sequence Region 
KIT 2270 
5’-GGA TGA TTT GCT GAG CTT 
CTC- 3’ 
Covers region with codon 
814 of KIT 
KIT 1 
5´-CAT TGA GTG CAG AAG GTT C-
3’  
Covers region with codon 
814 of KIT 
KIT 2 
5´-AAG AAG AGC AGG CAG AAG C- 
3´ 
Covers region with codon 
814 of KIT 
CSFR-1 
5´-TTC ACC ATC CAC AGG GCC 
AAG-3’ 
Covers region with codons 
567 & 569 of KIT 
CSFR-2 
5’-TTT TAA CTG GAC CTA CCT GG-
3’ 
Covers region with codons 
567 & 569 of KIT 
CSFR-3 
5’-TGG GAT GAC TTT CTG CAC TTT 
C-3’ 
Covers region with codons 
567 & 569 of KIT 
Y934F 
5’-GCA CCA AGC ACA TTT TTT 
CCA ACT TGG CAA AC-3’ 
Covers region with codon 
934 of KIT 
Y934R 
5’-GTT TGC CAA GTT GGA AAA 
AAT GTG CTT GGT GC-3’ 
Covers region with codon 
934 of KIT 
 
3. Patient Samples 
AML- and SM- derived patient peripheral blood, or bone marrow aspirate samples were 
obtained with prior patient consent.  Using ficoll gradient, low density mononuclear cells 
were isolated and provided to us by Drs. Ramon Tiu and Valeria Visconte at Cleveland 
Clinic (Cleveland, OH) and Dr. Scott Boswell (IUSM). 
 
4. Mice 
All mice were maintained under specific pathogen-free conditions at the Indiana 
University Laboratory Animal Research Center (Indianapolis, IN, USA), and were 
approved by the Institutional Animal Care and Use Committee of the Indiana University 
School of Medicine study numbers 3137 and 10311. 
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a. C57BL/6 
C57Bl/6 mice were purchased from Jackson Laboratory (Bay Harbor, ME, USA). 
All mice used in this study were between 6 to 12 weeks of age.   
b. Rac1flox/flox 
Rac1 deficient mice are embryonic lethal at day 8 (110). Using a Rac1flox/flox 
conditional mice were crossed with Mx1-Cre animals. These mice possess a flox allele 
that contains loxP sites on either side of exon 1 of the targeted Rac1 gene (111). To delete 
the flox sequences a Mx1-Cre promoter was used, in which Cre was driven by the 
interferon-inducible Mx1 promoter following three intraperitoneal injections of 200μg 
polyinosinic:polycytidylic acid (polyI:polyC) given at 48 hour intervals. 
c. Rac2-/- 
Rac2 null mice are a transgenic knockout mouse in C57BL/6 background strain 
(112). 
d. Rac1flox/flox;Rac2-/- 
To generate this strain Mx1-Cre;Rac1flox/flox mice were crossed with Rac2-/- 
transgenic knockout mice. Double heterozygote mice with Mx1-Cre were crossed to 
generate Mx1-Cre;Rac1flox/flox;Rac2-/- mice.  The Mx1-Cre double knockout mice strain 
was generated in which Rac1 transgene was under the control of Mx1-Cre promoter, with 
Rac2 being a complete transgenic knockout. 
e. Vav1-/- 
Guanine exchange factor, Vav1, knockout mice were in C57BL/6 background 
(113).   
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f. C3H/HeJ 
C3H/HeJ mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA).  
g. NOD/SCID (NOD.CB17-Prkdscid/SzJ) 
The NOD.CB17-Prkdscid/SzJ mice, commonly known as NOD/SCID, do not 
express the Prkdc gene. These mice lack functional T and B lymphoid cells. NOD genetic 
background results in reduced NK cell activity. These mice accept allogeneic and 
xenogeneic grafts effectively and have been used successfully to transplant a variety of 
normal and malignant human cells and tissues, including hematopoietic neoplasms (114). 
Mice were purchased from the In Vivo Therapeutics Core at Indiana University School of 
Medicine. 
h. NOD/SCID/IL2Rnull (NSG) (NOD.CB17-PrkdscidIl2rhtmWjl/SzJ) 
The NOD.CB17-PrkdcscidIl2rhtmWjl/SzJ mice, commonly known as NOD/SCID 
gamma (NSG), do not express the Prkdc gene nor the X-linked Il2rg gene. Histologically 
these mice have the absence of mature B and T lymphoid cells and lack functional natural 
killer cells. NSG mice lack some cystic structures in the thymus, have an absence of 
follicles in the spleen and a markedly diminished cellularity of the lymph nodes.  These 
mutant mice readily support engraftment of human CD34+ hematopoietic stem cells and 
represent a superior, long-lived model suitable for studying localized and systemic 
xenotransplantation (115).  Mice were purchased from the In Vivo Therapeutics Core at 
Indiana University School of Medicine. 
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i. NSG 3 Cytokine (CMV-IL3, CSF2, KITLG) (NOD.CB17-PrkdcscidIl2rhtmWjl(CMV-
IL3 CSF2, KITLG)1Eav.MloySzJ ) 
The NOD.CB17-PrkdcscidIl2rhtmWjl(CMV-IL3 CSF2, KITLG)1Eav.MloySzJ mice 
were developed at Cincinnati Children’s Hospital Medical Center. This NOD scid gamma 
(NSG) strain does not express the Prkdc gene nor the X-linked Il2rg gene, while allowing 
constitutive transgenic expression of three human cytokines stem cell factor (SCF), 
granulocyte macrophage colony-stimulating factor (GM-CSF), and interleukin-3 (IL-3). 
These mice harbor the same physiological properties as the NSG mice, while expressing 
three human cytokines leading to improvements in expansion of normal human myeloid 
cells and xenotransplantation of AML samples (116). Mice were purchased from the In 
Vivo Therapeutics Core at Indiana University School of Medicine. 
 
5.  Antibodies 
Table 2.3. Antibodies for Immunoblotting 
Primary Antibodies Company Molecular Weight 
KIT (C-19) 
 
Santa Cruz 
 
~145 kDa 
 
Rac1, clone 23A8 
 
Millipore 
 
~21 kDa 
 
Rac2 
 
Millipore ~21 kDa 
 
Vav (C-14) 
 
Santa Cruz 95 kDa 
 
-actin 
 
Santa Cruz 40 kDa 
 
Bcl-Xs/l (L-19) 
 
Santa Cruz 27 kDa 
Phospho-PAK Cell Signaling 68 kDa(Pak1) and 61kDa (Pak2) 
PAK Cell Signaling 68 kDa(Pak1) and 61kDa (Pak2) 
Phospho-Tyrosine Cell Signaling multiple 
Erk Cell Signaling 42 and 44 kDa 
Phospho-Erk Cell Signaling 42 and 44 kDa 
Akt Santa Cruz 60 kDa 
Jak2 Santa Cruz 125 kDa 
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Stat5 Santa Cruz 90 kDa 
Phospho-Stat5 Cell Signaling 90 kDa 
Bcl-2 Santa Cruz 28 kDa 
P85 Santa Cruz 85 kDa 
P-Akt Cell Signaling 60 kDa 
Bax Santa Cruz 20 kDa 
Rac1/2/3 Millipore 21 kDa 
Cdc42 Millipore 21 kDa 
 
Table 2.4. Horseradish Peroxidase Secondary Antibodies 
Secondary Antibody Vendor 
Goat Anti-Rabbit IgG horseradish peroxidase (HRP) Santa Cruz 
Goat Anti-Mouse IgG HRP Santa Cruz 
 
6. Commercially purchased kits 
Table 2.5. Commercially purchased kits 
Kit Vendor Catalog Number 
Plasmid Maxi-Prep Invitrogen K210007 
SuperSignal West Dura Extended 
Duration Substrate 
Thermo Scientific 34076 
Mini-prep Qiagen 27106 
Profection Mammalian Transfection 
System 
Promega E1200 
Rac1 Activation Assay Millipore 17-283 
Annexin V Apoptosis BD Pharmingen 556547 
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QuikChange Site-Directed 
Mutagenesis 
Agilent Technologies 200519 
 
B.  Methods 
1.  Cell Culture 
a. 32D Cells 
The 32D cell line is an immortalized interleukin-3 (IL-3) dependent myeloblast-
like cell line derived from murine bone marrow that was purchased from American Type 
Culture Collection (ATCC). These cells were cultured in RPMI-1640 (Invitrogen), 10% 
heat-inactivated fetal bovine serum (FBS) (Hyclone; Thermo Fisher Scientific), 2% 
penicillin/streptomycin (Invitrogen), and 10ng/ml murine IL-3 (PeproTech) (117).  Cells 
were grown at 37˚C and 5% CO2. 
b. P815 
The murine P815 lympho-blast like mastocytoma cell line was maintained in high 
glucose Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) supplemented with 
10% FBS (Hyclone; Thermo Fisher Scientific), 2% penicillin/streptomycin (Gibco) 
(118). Cells were grown at 37˚C and 5% CO2.  
c. HMC1.2 
The HMC1.2 cell line was established from the peripheral blood of a patient with 
mast cell leukemia (119). This cell line harbors a juxtamembrane domain mutation 
Gly560Val and an additional Asp816Val tyrosine kinase domain mutation in KIT (120-
122).  HMC-1.2 cells were cultured in RPMI 1640 (Invitrogen), supplemented with 15% 
heat-inactivated FBS (Hyclone; Thermo Fisher Scientific) and 1% 
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Penicillin/streptomycin at 37˚C and 5% CO2. The HMC1.2 cell line was a kind gift from 
Dr. Clifford Takemoto (John Hopkins Children’s Center, Baltimore, Maryland). 
d. Kasumi-1 
The Kasumi-1 cell line was derived from peripheral blood of a 7-year-old 
Japanese boy with AML in relapse after bone marrow transplantation.  Kasumi-1 
leukemic cells line has an 8;21 chromosome translocation that juxtaposes AML1 with 
ETO (or MTG8) gene, giving rise to the fusion gene AML1-ETO, hence the cells 
produce a chimeric AML1-ETO protein (123). The cell line also harbors an additional 
Asp822Lys   ligand-independent KIT activating mutation. The cells are positive for 
myeloperoxidase showing a morphology of myeloid maturation (124). The cell line was 
cultured in in RPMI 1640 (Invitrogen), supplemented with 15% heat-inactivated FBS 
(Hyclone; Thermo Fisher Scientific) and 1% Penicillin/streptomycin at 37˚C and 5% 
CO2. The Kasumi-1 cell line was a gift from Dr. Christopher Klug (University of 
Alabama at Birmingham, Birmingham, Alabama). 
e. Primary Low Density Mononuclear Cells  
Primary murine low density mononuclear cells (LDMNCs) were cultured in 
RPMI 1640 (Invitrogen), 20% FBS (Hyclone; Thermo Fisher Scientific), 2% 
Penicillin/streptomycin (Invitrogen), 100 ng/mL Stem Cell Factor (SCF), 100ng/mL 
Thrombopoietin (TPO), 50ng/mL Flt-3 Ligand (FL), and 4ng/mL murine interleukin-6 
(IL-6) all purchased from Peprotech (Rocky Hill, NJ). LDMNCs were maintained at 37˚C 
and 5% CO2.   
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f. Phoenix Packaging Cells 
Phoenix-GP is a second generation retrovirus producer cell line for the generation 
of ecotropic retroviruses. This cells line is highly transfectable with calcium phosphate 
mediated transfection and expresses only gag-pol but may be further pseudotyped with 
retroviral virions with envelope, this cell line was developed by Garry P Nolan at 
Stanford University. These cells were cultured in DMEM (Invitrogen), supplemented 
with 10% FBS (Hyclone; Thermo Fisher Scientific), 1% L-glutamine, and 2% 
penicillin/streptomycin on gelatin-coated, tissue culture-treated 10cm plates at 37˚C and 
5% CO2.   
g. Patient-derived leukemic blasts 
Cells from the bone marrow and peripheral blood (PB) of patients with systemic 
mastocytosis (SM) were cultures in 100ng/mL of human recombinant SCF in IMDM 
supplemented with 20% heat-inactivated FBS and 2% penicillin/streptomycin in tissue 
culture treated 6-well plates at 37˚C and 5% CO2.   
h. MV4;11 
MV4;11 cell line was established from the blast cells of a 10-year-old male with 
biphenotypic B-myelomonocytic leukemia harboring a translocation t(4;11). These cells 
express a homozygous 30-base pair (bp) FLT3-ITD mutation. Cultures were maintained 
in RPMI-1640 (Invitrogen), supplemented with 10% heat-inactivated FBS (Hyclone; 
Thermo Fisher Scientific) and 1% Penicillin/streptomycin at 37˚C and 5% CO2.   
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2. Thymidine Incorporation Assay   
Proliferation was assessed by conducting a thymidine incorporation assay. Cells 
were washed and starved in IMDM containing 0.2% BSA without serum or growth 
factors for 6 hours. Cells (5 x 104) were plated in replicates of four in a 96-well plate in 
200 L complete medium (IMDM, 10% FBS, 2% Penicillin-Streptomycin) either in the 
presence or absence of indicated growth factors with or without inhibitors. Cells were 
cultured for 48 hours and subsequently pulsed with 1.0 Ci (0.037 MBq) [3H] thymidine 
(Perkin Elmer, Shelton, CT) for 6 hours. Cells were harvested using an automated 96-
well cell harvester (Brandel, Gaithersburg, MD) and thymidine incorporation was 
determined as counts per minute (CPM).  
 
3. Subcloning 
cDNA encoding wild type murine KIT  or KITD814V were subcloned from a 
murine stem cell virus (MSCV)-based bicistronic retroviral vector, MIEG3, with an 
enhanced green fluorescent protein (EGFP) tag to a bicistronic retroviral vector MIEG3 
with a hCD4 tag (125). The EcoR1-NotI fragment containing the KITD814V mutation 
was verified by sequencing and ligated into the EcoR1-NotI sites of the MIEG3-hCD4 
retroviral vector. pCMV6 expressing a Myc-tagged kinase-dead (K299R) Pak was a gift 
from Jeffrey Field (University of Pennsylvania, Philadelphia, Pennsylvania, USA) (126). 
Plasmids encoding RacN17 have been previously described (104). The cDNAs were 
subcloned into a bicistronic retroviral vector, MIEG3, upstream of the internal ribosome 
entry site (IRES) and the EGFP gene (125) or human CD4 gene. The pLNCX2-
32 
 
PAK1T423E-IRES2- EGFP plasmid has been described (127). Plasmids encoding 
MIEG3-RacN17 and MSCV-puro-RacV12 have been previously described (128). 
 
4. Retroviral Supernatant Production 
Retroviral supernatants for the transduction of 32D cells and primary BM 
LDMNCs were generated with a Phoenix ecotropic packaging cell line transfected with 
retroviral vector plasmids using a calcium phosphatase transfection kit (ProFection® 
Mammalian Transfection System, Promega, Madison, WI). Supernatants were collected 
48 hours after transfection and filtered through 0.45-μm membranes. Supernatants were 
used fresh or following storage at -80°C. 
 
5. Retroviral Infection 
a. Primary murine bone marrow low density mononuclear cells 
BM LDMNCs were suspended in non-tissue culture plates along with 
prestimulation media (IMDM containing 20% FBS and 2% penicillin-streptomycin 
supplemented with 100ng/ml TPO, SCF, 50ng/mL Flt3 Ligand, and 4ng/mL IL-6) for 2 
days prior to two rounds of retroviral infection using 2ml of retroviral particles encoding 
pMIEG3-WT KIT, pMIEG3-KITD814V, pLNCX2-PAK1T423E, or MSCVpuro-RacV12 
plasmids on fibronectin fragments (Retronectin; Takara). Forty-eight hours after the last 
infections, cells expressing WT KIT or KITD814V were sorted to homogeneity based on 
EGFP expressing. MSCV puro cells were selected with 1µg/ml puromycin (Sigma-
Aldrich) for an additional 48 hours. 
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b. 32D cells  
32D cells were infected with 2 ml of high-titer virus supernatant in the presence 
of 8 µg/ml polybrene in complete media (RPMI 1640 containing 10% FBS and 2% 
penicillin-streptomycin supplemented with 10 ng/ml murine IL-3), and plated into 6-well 
plates. The plates were centrifuged for one hour at 1,200 rpm to ensure the viral particles 
and cells were in close proximity prior to incubation at 37˚C for 5 hours.  Cells were 
collected and incubated in fresh complete media and IL-3 overnight at 37 ˚C. Infection 
was repeated the following day before cells were sorted and expanded. EGFP-positive 
cells or human CD4-positive (hCD4-positive) cells were sorted to homogeneity and used 
in the experiments. 
 
6. Cell Sorting    
Retroviral transduced cells were collected and sorted using fluorescence-activated 
cell sorting (FACS) analysis, collecting either enhanced green fluorescent protein 
positive (EGFP+) or hCD4 positive expressing cells. 
 
7.  Immunoprecipitation and Western Blotting 
0.5-1mg total cell lysates were immunoprecipitated with anti-p85, anti-Vav1, or 
anti- KIT antibody and protein-A or protein-G sepharose beads (GE Healthcare) in Cell 
Lysis Buffer (consisting of 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1mM Na2EDTA, 
1% Triton, 1 mM EGTA, 2.5 mM sodium pyrophosphate, 1mM -glycerophosphate, 
1mM Na3VO4, 0.1 mM leupeptin) supplemented with 10 µl/ml Protease Inhibitor 
Cocktail (Sigma-Aldrich) overnight while rotating at 4˚C.  The following day, beads were 
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centrifuged and washed several times with cold Cell Lysis Buffer, and 
immunoprecipitated proteins resuspended in sample buffer.  Immunoprecipitated 
products were boiled before loaded and run on SDS-PAGE gels. The gels were 
transferred to nitrocellulose which was blocked in 5% nonfat milk in TBS, following 
blocking the membranes were incubated with the indicated primary antibody, followed 
by incubation with secondary HRP-linked antibodies (Cell Signaling, Beverely, MA). 
Detection of protein bands was performed using Super Signal West Dura Extended 
Duration Chemiluminescence (Thermo Scientific, Rockford, IL). Chemiluminenesce 
signals were detected with a BioRad BioImager and analyzed using ImageLab software. 
 
8. Apoptosis Assay 
Apoptosis was assessed following starvation of cells and subsequently plating 
them in 24-well plates (2 x 105 cells) in 2 mL of complete media (IMDM, 10% FBS, 2% 
Penicillin/Streptomycin) in the absence of growth factors. Apoptosis was determined 
following staining with an Annexin V Apoptosis Detection kit (BD Biosciences 
Pharmingen, San Diego, CA, USA) according to the manufacturer’s protocol and 
analyzed by flow cytometry. 
 
9. Cell Cycle Assay 
For cell cycle assay, cells were deprived of serum and growth factors and plated 
in 24-well plates (2x105 cells/ well) in 2 mL of complete media in the absence of growth 
factors for 48 hours at 37°C. Cells were collected into individual 5 mL polystyrene tubes 
(FACS tubes), washed with PBS and the cells were stained with propidium iodide (PI) 
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staining solution (0.1 µg/ml PI, 0.6% NP-40 , and 100µg/ml DNase-free RNase A) in 
PBS for 10 min at room temperature. Stained cells were analyzed on a FACSCaliber flow 
cytometer (BD Biosciences, San Jose, CA) and data was analyzed using the CellQuest 
software or ModFit LT for Mac (Verity Software House, Topsham, ME). 
 
 
10. Transplantation Assay 
a. Syngeneic Transplantation Model  
Transplantation into C3H/HeJ mice was carried out by administering a single i.v. 
injection of 2 × 106 32D cells bearing WT KIT or KITD814V with or without RacN17 or 
PakK299R, or 1 × 106 KITD814V-bearing 32D cells cultured overnight with DMSO 
(vehicle), 25 μM NSC23766, or 2.5 μM EHop-016. Mice were harvested at the time of 
moribundity, and PB, femurs, spleen, lungs, and liver were collected for histopathological 
and flow cytometric analysis. 
b. Primary Murine Transplantation Model 
WT or Vav1–/–, Rac2–/–, and Mx1-cre;Rac1flox/flox;Rac2–/– C57BL/6 mice that were 
6-to-8 weeks of age were given a single i.p. injection of 150 mg/kg of 5-fluorouracil (5-
FU) (APP Pharmaceuticals). BM cells were collected 72 hours after injection from the 
tibia, femur, and iliac crest, and LDMNCs were prestimulated for 2 days in 
prestimulation media, as described above prior to transduction with retrovirus encoding 
WT KIT or KITD814V. After two rounds of infection as described above, cells were 
sorted to homogeneity, and 1 × 106 cells were counted and mixed with 1 × 105 supporting 
fresh splenocytes. 
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11. Flow Cytometry 
Cells expressing either WT KIT or KITD814V were incubated for 30 minutes at 
4°C in 10% rat serum before staining with a combination of the indicated antibodies. 
Cells were washed two times with 0.2% BSA in PBS (Sigma-Aldrich) and analyzed by 
FACS (FACSCaliber, and LSR; BD). 
 
12. Rac Activation Assay 
Rac Activation Assays were performed using the manufactures directions 
(Millipore, catalog number 17-218).  Cells were collected on ice and washed with PBS, 
and lysed with 500 µl of Mg2+ Lysis Buffer for every 107cells. Lysates were centrifuged 
to remove cellular debris and the supernatants were quantified using BCA assay buffer. 
Lysates were set aside as input and lysates were immunoprecipitated with 20-30µg of the 
GTPase Protein Binding Domain/agarose slurry and incubated for 45 minutes at 4°C with 
gentle agitation. The agarose beads were pelleted by centrifugation at 14,000 rpm for 10 
seconds. The supernatant was discarded and the beads were washed with MLB three 
times. The beads were resuspended in 40 µl of 2X Laemmli reducing sample buffer and 
boiled for 5 minutes to liberated the bound protein and run by immunoblot analysis, 
probing with anti-Rac1, Rac2, Rac1/2/3 and cdc42 antibodies (EMD Millipore) 
 
13. Site-directed mutagenesis of Chimeric KIT receptors 
Chimeric KIT receptors (CHR) were previously generated in our laboratory as 
described by Tan et al.(128). Utilizing CHR receptors as templates we introduced a 
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KITD814V mutation by mutagenesis. We generated the mutant CHRD814V and 
CHRD814V with none (CHRD814V-F7) or single intracellular tyrosine add-back 
mutants using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, 
USA) and the following primer pair (forward: 5'GGGCTAGCCAGAGTCATCAGGAAT 
GATTCG3'; reverse: 5'-CGA ATCATTCCTGATGACTCTGGCTAGCCC-3'). 
Generation of plasmids containing the KITD814V mutation was verified by sequencing 
described in Table 2.2. 
 
14. Statistical Analysis  
All graphical data were evaluated by paired Student's t-test and results were 
considered significantly different with p-value <0.05.  Data are expressed as mean 
values± standard deviations (SD) unless otherwise stated. Sigma Plot 12.0 software 
(Systat Software Inc, San Jose, CA) was used for statistical analysis.  All data are 
represented as mean values ± SD. Survival of transplanted mice cohorts were compared 
using a Kaplan–Meier survival analysis using a log rank test in which statistical 
significance was determined as p-values <0.05 by log-rank test. 
 
15. Study Approval 
Mice were maintained under specific pathogen-free conditions at the Indiana 
University Laboratory Animal Research Center, and this study was approved by the 
IACUC of the Indiana University School of Medicine. Samples from AML and SM 
patients were collected after obtaining written informed consent as approved by the 
Institutional Review Board of the Cleveland Clinic/Case Comprehensive Cancer Center 
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and the Institutional Review Board of the Indiana University School of Medicine (Study# 
1468). AML and SM patient samples were obtained in accordance with the Declaration 
of Helsinki. 
39 
 
CHAPTER THREE 
ROLE OF INTRACELLULAR TYROSINE RESIDUES IN ONCOGENIC KIT-
INDUCED TRANSFORMATION 
 
3.A ABSTRACT 
Gain-of-function mutations in KIT receptor in humans are associated with 
gastrointestinal stromal tumors (GIST), systemic mastocytosis (SM), and acute 
myelogenous leukemia (AML). The intracellular signals that contribute to oncogenic KIT 
induced myeloproliferative disease (MPN) are poorly understood. Here, we show that 
oncogenic KITD814V induced MPN occurs in the absence of ligand stimulation. The 
intracellular tyrosine residues are important for KITD814V induced MPN, albeit to 
varying degrees. Among the seven intracellular tyrosines examined, tyrosine 719 alone 
plays a unique role in regulating KITD814V induced proliferation and survival in vitro, 
and MPN in vivo. Importantly, the extent to which AKT, ERK and Stat5 signaling 
pathways are activated via the seven intracellular tyrosines in KITD814V impacts the 
latency of MPN and severity of the disease. Our results identify critical signaling 
molecules involved in regulating KITD814V induced MPN, which might be useful for 
developing novel therapeutic targets for hematologic malignancies involving this 
mutation.  
 
 
 
40 
 
3.B INTRODUCTION 
The proto-oncogene KIT belongs to the receptor tyrosine kinase class III family, 
which includes the M-CSFR, the PDGFR, as well as FLT3 (68). The KIT receptor plays a 
crucial role in cell proliferation, differentiation, survival and migration through activation 
of diverse signaling pathways (56). Binding of its ligand, stem cell factor (SCF), induces 
KIT receptor dimerization and autophosphorylation on intracellular tyrosine residues 
leading to the recruitment and docking of SH2 containing signaling molecules to the 
seven critical intracellular tyrosines (129). Although the individual and combined 
importance of these tyrosines in normal KIT receptor signaling is beginning to emerge; 
the role of these tyrosines in oncogenic KIT induced MPN is poorly understood. 
Furthermore, it is unclear whether these tyrosines play a unique, redundant or 
overlapping function in inducing MPN.  
Activating mutations in KIT receptor have been shown to be involved in various 
human diseases including GIST, SM, and AML (45, 130-132). An activating KIT 
mutation within the tyrosine kinase domain, such as KITD814V in mice or KITD816V in 
humans, results in ligand independent tyrosine kinase activity leading to constitutive 
autophosphorylation and activation of downstream signaling pathways (76, 89). As a 
result, KITD814V bearing cells demonstrate ligand independent proliferation in vitro and 
MPN in vivo (75, 76, 89, 133, 134). However, the intracellular mechanisms that 
contribute to KITD814V induced MPN are not known. In addition, primary 
hematopoietic stem and progenitors (HSC/Ps) bearing KITD814V show a further 
increase in proliferation in the presence of KIT ligand, SCF, relative to cells grown in the 
absence of SCF (133), which suggests that endogenous ligand stimulation may contribute 
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to oncogenic KIT induced transformation in vivo. Therefore, it is still unclear whether 
ligand independent growth observed in vitro via KITD814V is sufficient to induce MPN 
in vivo or whether presence of SCF is necessary to drive MPN.  
Although KIT mutations within the juxtamembrane domain found in GIST are 
highly sensitive to inhibition by imatinib (i.e. Gleevec), KIT mutations within tyrosine 
kinase domain involved in SM and AML, including KITD816V, are resistant to imatinib 
treatment (83, 135, 136). Currently, there are no therapies available for human diseases 
involving KITD816V mutation. Thus, it is important to identify signaling pathways that 
are involved in KITD814V induced MPN to develop novel therapeutic targets for 
diseases involving this mutation. Utilizing biochemical and genetic approaches, we 
demonstrate that endogenous ligand (i.e. SCF) binding is dispensable for KITD814V 
induced MPN. Furthermore, the intracellular tyrosine residues are important for 
KITD814V induced MPN, albeit to varying degrees. Among the seven intracellular 
tyrosines examined, tyrosine 719 alone plays a unique role in regulating KITD814V 
induced proliferation in vitro, and MPN in vivo. Importantly, tyrosine 719 is vital for the 
activation of PI3K and Stat5 downstream from KITD814V. Our results identify critical 
signaling molecules downstream from KITD814V, which might be useful for developing 
therapeutic targets for hematologic malignancies involving oncogenic forms of KIT.  
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3.C RESULTS 
Construction of wild-type and mutant KIT chimeric receptors 
We and others have previously shown that KITD814V is sufficient to induce 
ligand independent growth in vitro as well as myeloproliferative disease (MPN) in vivo 
(75, 76, 89, 97, 133). It is however unclear whether KITD814V induced ligand 
independent growth observed in vitro is sufficient to cause MPN in vivo or whether 
presence of endogenous SCF induced signals are essential for the development of MPN. 
To determine the contribution of ligand independent growth in KITD814V induced MPN 
in vivo, we generated a chimeric KIT receptor (CHR) in which the extracellular domain 
of KIT was replaced with the extracellular domain of human macrophage colony 
stimulating factor receptor (h-MCSFR) to inhibit the endogenous binding of murine SCF, 
but to maintain the transmembrane and intracellular domains of the murine KIT receptor 
(69, 72) (Figure 3.1.A). This receptor allows studying the ligand independent functions of 
KIT receptor in vivo as it maintains the intracellular functions of KIT receptor intact 
without endogenous binding of murine SCF or M-CSF, but is specifically activated by 
human M-CSF (69, 72). The wild-type chimeric receptor (WT CHR) is functionally and 
biochemically similar to the wild-type endogenous KIT receptor as previously reported 
(69, 72). In addition, we constructed a mutant chimeric receptor (CHRD814V) that 
contains an oncogenic mutation of aspartic acid to valine at residue 814 of the WT CHR 
(Figure 3.1.A), this mutant was verified by sequencing (Figure 3.1.B). Parental and 
chimeric KIT receptors with or without D814V mutation were cloned into a bicistronic 
retroviral vector, MIEG3, which expresses EGFP through an internal ribosome entry site 
as previously described (69, 72).  
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Figure 3.1 Construction of chimeric CHRD814V receptor. 
 
 (A) Schematic of WT CHR and CHRD814V receptors. Wild-type (WT) and oncogenic 
chimeric (CHR) KIT receptors were constructed by replacing the extracellular ligand 
binding domain of murine WT KIT or KITD814V with the ligand binding domain of 
human M-CSF receptor. (B) Mutagenesis of an aspartic acid (D) to valine (V) at 
indicated position 814 (indicated by arrow) by site-directed mutagenesis using WT CHR 
as a template. 
 
GENE ID: 16590 Kit | kit oncogene [Mus musculus] (Over 100 PubMed links) 
 
 Score =  449 bits (1154),  Expect(2) = 8e-125 
 Identities = 239/263 (90%), Positives = 241/263 (91%), Gaps = 3/263 (1%) 
 Frame = +2 
 
Query  8    STEPSCDSSNEYMDMKPGVSYVVPTKTDKRRSARIDSYIERDVTPAIMeddelaldlddl  187 
            STEPSCDSSNEYMDMKPGVSYVVPTKTDKRRSARIDSYIERDVTPAIMEDDELALDLDDL 
Sbjct  712  STEPSCDSSNEYMDMKPGVSYVVPTKTDKRRSARIDSYIERDVTPAIMEDDELALDLDDL  771 
 
Query  188  lSFSYQVAKGMAFLASKNCIHRDLAARNILLTHGRITKICDFGLARVIRNDSNYVVKGNA  367 
            LSFSYQVAKGMAFLASKNCIHRDLAARNILLTHGRITKICDFGLAR IRNDSNYVVKGNA 
Sbjct  772  LSFSYQVAKGMAFLASKNCIHRDLAARNILLTHGRITKICDFGLARDIRNDSNYVVKGNA  831 
 
Query  368  RLPVKWMAPESIFSCVYTFESDVWSYGIFLWELFSLGSSPYPGMPVDSKFYKMIKEGFRM  547 
            RLPVKWMAPESIFSCVYTFESDVWSYGIFLWELFSLGSSPYPGMPVDSKFYKMIKEGFRM 
Sbjct  832  RLPVKWMAPESIFSCVYTFESDVWSYGIFLWELFSLGSSPYPGMPVDSKFYKMIKEGFRM  891 
 
Query  548  VSPEHAPAEMYDVMKTCWDADPLKRPTFKQVVQLIEKQISDSTKHIYSNLGKLQPXPQRT  727 
            VSPEHAPAEMYDVMKTCWDADPLKRPTFKQVVQLIEKQISDSTKHIYSNL    P P+   
Sbjct  892  VSPEHAPAEMYDVMKTCWDADPLKRPTFKQVVQLIEKQISDSTKHIYSNLANCNPNPENP  951 
 
Query  728  PVVGGPFR---EGSTRWXAAPLL  787 
             VV    R    GS+     PLL 
Sbjct  952  VVVDHSVRVNSVGSSASSTQPLL  974 
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Ligand independent growth is sufficient to induce KITD814V induced MPN in vivo 
We first verified whether our constructed chimeric KIT receptors function similar 
to their wild-type and KITD814V counterparts. Viral supernatants expressing these 
receptors were used to infect an immortalized, murine, interleukin-3 (IL-3) dependent 
myeloid cell line (32D) which is absent of intrinsic KIT expression; transduced cells were 
sorted to homogeneity based on EGFP expression and used to perform functional and 
biochemical studies. 32D cells are particularly useful because they lack endogenous wild-
type KIT expression. Transduced cells were observed to have comparable levels of 
protein expression of the wild-type and chimeric KIT receptors. To verify that our 
constructed chimeric KIT receptors function similar to their wild-type and KITD814V 
counterparts, we performed proliferation assay in 32D myeloid cells bearing parental or 
chimeric KIT receptors with or without D814V mutation by assessing thymidine 
incorporation. We starved these cells of serum and growth factors for six hours and 
performed a thymidine incorporation assay (2x104 cells/200 µl) in the absence of growth 
factors and incubated the cells for forty-eight hours at 37°C. The cells were pulsed with 
1µ𝐶𝑖 tritiated thymidine and incubated for 6 hours at 37°C, prior to analysis using an 
automated 96-well cell harvester (Brandel, Gaitgersburg, MD). As expected, cells bearing 
KITD814V or CHRD814V showed similar levels of ligand independent growth (Figure 
3.2.A). In contrast, cells bearing WT KIT or WT CHR showed minimal thymidine 
incorporation in the absence of growth factors (Figure 3.2.A). In addition, cells bearing 
WT CHR showed increased growth in the presence of human M-CSF, but not murine M-
CSF (Figure 3.2.B). These findings demonstrate that chimeric receptors (WT CHR and 
CHRD814V) function in a manner similar to their parental counterparts with respect to 
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ligand independent growth and specifically respond to human M-CSF, but not murine M-
CSF. Therefore, these chimeric receptors could be used to determine the impact of ligand 
independent growth in KITD814V induced MPN in vivo. 
 
 
Figure 3.2. Intracellular tyrosine residues of KIT receptor are essential for 
KITD814V-induced ligand-independent growth in vitro. 
 
(A) Cells bearing KITD814V and CHRD814V exhibit similar ligand independent 
growth. Cells expressing WT KIT, KITD814V, WT CHR or CHRD814V receptors were 
starved and subjected to proliferation assay by thymidine incorporation in the absence of 
growth factors as described in methods. Bars denote the mean thymidine incorporation 
(CPM ± SD) from one of three independent experiments performed in quadruplicates. *p-
value<0.05, KITD814V or CHRD814V vs. WT KIT or WT CHR. (B) Chimeric KIT 
receptor responds specifically to human M-CSF, but not to murine M-CSF. Cells 
expressing MIEG3 vector or WT CHR were starved in serum- and growth factor-(GF) 
free media for 6 hours and cultured in the presence or absence of human or murine M-
CSF for 48 hours and analyzed for proliferation by thymidine incorporation. Bars denote 
the mean thymidine incorporation (CPM ± SD) from one of at least three independent 
experiments performed in quadruplicate. *p-value<0.05. 
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To determine the role of ligand independent growth in KITD814V induced MPN 
in vivo, we used a murine transplantation model that we have previously described (97). 
LDMNC from 5-FU-treated C57BL/6 mice were transduced with WT CHR, WT KIT, 
KITD814V or CHRD814V, and sorted cells were transplanted into lethally irradiated 
recipient mice. Transplanted mice were monitored for MPN development and survival. 
Consistent with our previous results, all mice transplanted with WT CHR cells appeared 
normal and healthy past 180 days post transplantation (data not shown). In contrast, all 
recipient mice transplanted with CHRD814V bearing cells died within 81 days of 
transplantation (Figure 3.3.A). No significant difference in the survival of mice 
transplanted with cells bearing KITD814V or CHRD814V was observed suggesting that 
endogenous SCF mediated stimulation of KITD814V receptor is not necessary for 
KITD814V induced MPN in vivo. Mice transplanted with cells expressing CHRD814V 
developed a series of fatal diseases, including MPN, as seen by a significant increase in 
white blood cell counts compared to WT CHR controls (Figure 3.3.B). In addition, mice 
transplanted with CHRD814V-bearing cells showed splenomegaly (Figure 3.3.C). Figure 
3.4.A shows representative pictures of spleen and liver from mice transplanted with cells 
bearing either WT CHR or CHRD814V.  
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Figure 3.3. KITD814V induced MPN is not dependent on endogenous SCF. 
 
(A) Kaplan–Meier analysis of mice transplanted with 5-fluorouracil (5-FU) derived 
primary hematopoietic stem and progenitor cells bearing WT KIT, KITD814V or 
CHRD814V. The percentage of surviving mice (y-axis) is plotted with respect to post-
transplantation time in days (x-axis). Mice transplanted with WT KIT (n=8), KITD814V 
(n=7) or CHRD814V (n=9) expressing cells succumbed to a fatal MPN within 81 days of 
transplantation. No significant difference between the survival of mice bearing 
KITD814V or CHRD814V was observed. (B) & (C) enhanced peripheral blood (PB) cell 
counts and splenomegaly in mice transplanted with cells bearing CHRD814V (n=9) 
compared to WT CHR (n=4 to 6). *p-value<0.05.  
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Histologic analysis of bone marrow (BM), spleen, liver and lungs from mice 
transplanted with CHRD814V bearing cells showed signs of MPN including infiltration 
of immature cells in BM and disruption of the normal architecture of red and white pulp 
in spleen (Figure 3.4.B). Furthermore, flow cytometric analysis of peripheral blood, 
spleen and BM from mice transplanted with cells bearing CHRD814V showed increase 
in the presence of Gr-1 and Mac-1-positive cells compared to mice transplanted with 
cells bearing WT CHR (Figure 3.4.C). Some mice transplanted with cells bearing 
CHRD814V also demonstrated erythroleukemia, B-cell and T-cell lymphomas in 
addition to MPN, similar to other published models of oncogene-induced MPN (data not 
shown) (137). Taken together, these results indicate that KITD814V mutation does not 
require a direct engagement with its ligand SCF to induce MPN in vivo.  
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Figure 3.4. CHRD814V induced elevated WBC counts and splenomegaly. 
 
(A) Representative pictures of spleen and liver from mice transplanted with cells bearing 
WT CHR (n=4) and CHRD814V (n=9). (B) Histopathologic analysis demonstrating 
MPN phenotype in mice transplanted with cells bearing CHRD814V. Bone marrow, 
spleen, liver and lungs from the mice transplanted with cells bearing WT CHR or 
CHRD814V were harvested, fixed in 10% buffered formalin, sectioned, and stained with 
hematoxylin and eosin. Shown are representative tissue sections from WT CHR and 
CHRD814V transplanted mice. (C) Flow cytometric analysis on cells derived from 
indicated tissues from mice bearing WT CHR or CHRD814V.  
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Intracellular tyrosine residues in KITD814V are essential for ligand independent 
growth in vitro  
We next focused our studies to determine the importance of intracellular tyrosine 
residues in KITD814V induced ligand independent growth. To address this, we 
constructed a CHRD814V mutant receptor (CHRD814V-F7) in which all the intracellular 
tyrosine residues were converted to phenylalanine by site directed mutagenesis as shown 
in Figure 3.5.A. 32D cells were transduced with WT CHR, CHRD814V or CHRD814V-
F7, sorted to homogeneity based on EGFP expression and used to perform proliferation 
assay. Consistent with our earlier result (Figure 3.2.A), cells bearing CHRD814V, but not 
WT CHR, showed ligand independent growth (Figure 3.6.A). However, conversion of all 
the seven intracellular tyrosine residues in CHRD814V to phenylalanine (CHRD814V-
F7) resulted in loss of ligand independent growth (Figure 3.6.A). These results suggest 
that intracellular tyrosine residues in KITD814V are essential for ligand independent 
growth. 
To identify which of the tyrosine residue plays a critical role in KITD814V 
induced ligand independent growth in vitro and transformation in vivo, we generated 7 
different single tyrosine add-back mutants at residues 567, 569, 702, 719, 728, 745 and 
934 in the KIT intracellular domain using CHRD814V-F7 as the template (Figure 3.5.A). 
These CHRD814V mutant receptors were designated CHRD814V-Y567, CHRD814V-
Y569, CHRD814V-Y702, CHRD814V-Y719, CHRD814V-Y728, CHRD814V-Y745 
and CHRD814V-Y934. 32D cells, which lack endogenous KIT receptor, were infected 
with these mutant CHRD814V receptors and sorted to homogeneity. A similar level of 
expression of these receptors was observed by western blot analysis (Figure 3.5.B). As 
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seen in Figure 3.6.B, 32D cells bearing only the chimeric receptor harboring tyrosine 
residue at position 719 (CHRD814V-Y719) was sufficient to induce ligand independent 
growth to a level similar to cells bearing the CHRD814V receptor. The other tyrosine 
add-back CHRD814V receptors induced modest to no ligand independent proliferation 
(Figure 3.6.B). Similar results were observed in transduced primary HSC/Ps from KitW-
sh/W-sh mice lacking endogenous KIT (Data not shown). In addition, cells bearing 
CHRD814V showed significantly increased survival compared to WT CHR bearing cells 
in the absence of growth factors and loss of intracellular tyrosine residues in CHRD814V 
(CHRD814V-F7) had significant decreased in ligand independent survival (Figure 
3.7.A). Among all the single tyrosine add-back CHRD814V receptors, CHRD814V-
Y719 was the only receptor whose expression maintained survival at a level similar to 
that of CHRD814V receptor (Figure 3.7.A). There was no significant difference in the 
cycling status of cells bearing various mutant CHRD814V receptors, including 
CHRD814V and CHRD814V-Y719, when grown in the absence of growth factors 
(Figure 3.7.B). These results demonstrate that intracellular tyrosine residues in 
KITD814V receptor are essential for ligand independent growth. Among these tyrosine 
residues, tyrosine at residue 719, which is the binding site for class IA PI3K regulatory 
subunit p85α, is sufficient to rescue ligand independent proliferation in vitro to 
CHRD814V levels. 
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Figure 3.5. Schematic of mutant CHRD814V receptors and expression in 32D cells. 
 
(A) Schematic of mutant CHRD814V receptors. In the single tyrosine add-back mutant 
CHRD814V receptors, phenylalanine at indicated positions in the CHRD814V-F7 
receptor were restored to tyrosine on an individual basis. (B) Equal amounts of protein 
lysates from cells bearing MIEG3 vector or indicated CHRs were subjected to Western 
Blot analysis using an anti-KIT antibody.  
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Figure 3.6. Differential contributions of intracellular tyrosine residues in KIT 
receptor to KITD814V-induced ligand-independent growth in vitro. 
 
(A) 32D cells bearing the WT CHR, naked CHRD814V-F7, or CHRD814V were starved 
of serum and growth factors for 6 hours and subjected to thymidine incorporation assay 
in the presence or absence of 5 ng IL-3. (B) Cells bearing the indicated CHRD814V add-
backs were grown in the absence of growth factors. Bars denote the mean thymidine 
incorporation (cpm ± sd) *p-value<0.05. 
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Figure 3.7. Reduced survival, but normal cycling of cells bearing various chimeric 
KIT receptors. 
 
Cells bearing the indicated chimeric receptors were starved of serum and growth factors 
and cultured for 48 hours in the absence of growth factors. (A) Cells were harvested and 
stained with anti-Annexin V and 7-Amino-Actinomycin D (7-AAD) antibody followed 
by flow cytometric analysis. Double negative cells in the lower left quadrant are indicated 
as surviving cells.  Representative dot blots are shown (n=2, *p<0.05). (B) Cells were 
stained with propidium iodide followed by flow cytometric analysis. Percentage of cells 
in S-phase is indicated. No significant difference in the cycling of cells bearing different 
chimeric KIT receptors was observed (n=2). 
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Intracellular tyrosine residues in KITD814V contribute to MPN in vivo, albeit to 
varying extent 
To determine the physiologic role of the intracellular tyrosine residues in 
KITD814V induced MPN in vivo, we transduced primary HSC/Ps from 5-FU-treated 
C57BL/6 mice with WT CHR, CHRD814V or CHRD814V with none or single tyrosine 
add-back mutants. Transduced cells showing similar transduction efficiencies were sorted 
to homogeneity and transplanted into lethally irradiated recipient mice. Mice were 
monitored for MPN development and survival. While mice transplanted with cells 
bearing WT CHR showed no signs of disease and survived throughout the study, mice 
transplanted with cells bearing CHRD814V (red line) succumbed to death within 80 days 
of transplantation and developed a fatal MPN (Figure 3.3.A and Figure 3.8). In addition, 
mice transplanted with cells bearing CHRD814V-F7 (black line), which lack all the 
seven intracellular tyrosine residues, significantly delayed MPN development and 
prolonged overall survival (Figure 3.8. Panel 1). In the CHRD814V-F7 group, only 70% 
of the mice died within 180 days of transplantation and remaining 30% showed no signs 
of disease and appeared normal. These data suggest that the intracellular tyrosine residues 
in KITD814V are critical for efficient transformation in vivo. 
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Figure 3.8. Intracellular tyrosine residues in KIT receptor are essential for 
KITD814V-induced MPN in vivo. 
 
Kaplan-Meier survival analysis of mice transplanted with cells bearing indicated single 
tyrosine add-back mutant CHRD814V receptors (n=4-13 per group). Results show that 
loss of seven tyrosine residues in CHRD814V significantly delayed MPN development 
and prolonged overall survival (140 days median survival, n=13, *p-value<0.05. 
Presence of Y719 alone is sufficient for transformation in vivo (55 days median survival, 
n=7, *p-value<0.05. Compared with CHRD814V, restoration of Y567, Y569, Y728, and 
Y934 demonstrated a significant delay in disease onset in transplanted mice (95-128 days 
median survival, n= 4-13, *p-value<0.05). There is a modest delay in the survival of the 
recipient mice bearing CHRD814V-Y702 compared with CHRD814V-bearing mice (76 
days median survival, n=4, p=0.077).  
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Consistent with in vitro proliferation, among all the mice transplanted with cells 
bearing various CHRD814V mutant receptors, only recipient mice expressing 
CHRD814V-Y719 (blue line) showed similar MPN progression and survival as the 
CHRD814V bearing mice (Figure 3.8. Panel 5). The median time of survival in these two 
groups was 60 days for CHRD814V vs 55 days for CHRD814V-Y719. In addition, 
recipient mice with cells bearing CHRD814V-Y567, CHRD814V-Y569, CHRD814V-
Y728CHRD814V-Y745 and CHRD814V-Y934 showed a significant delay in MPN 
development and survival compared to CHRD814V bearing mice (Median time of 
survival 105, 128,95,104 and 68 days, respectively, *p-value<0.05). Restoration of Y702 
demonstrated a modest but non-significant delay in the disease onset compared to 
KITD814V bearing mice (Median time of survival 76 days, p=0.077). Consistent with the 
survival data, histological analysis of bone marrow, spleen, liver and lungs from the 
recipient mice transplanted with cells bearing various single tyrosine add-back 
CHRD814V mutants showed variable degree of infiltration of immature cells relative to 
CHRD814V bearing mice or CHRD814V-Y719 bearing mice (Figure 3.4.B and Figure 
3.9). These results suggest that among the seven intracellular tyrosine residues in 
KITD814V, tyrosine residue at 719 is sufficient to induce fully penetrant MPN in vivo. 
Other tyrosine residues at 567, 569, 702, 719, 728, 745 and 934 do contribute to 
KITD814V induced MPN, however to a lesser extent, resulting in delayed disease onset 
and reduced severity.  
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Figure 3.9. Immunohistopathologic analysis of BM, spleen, liver and lung from mice 
transplanted with cells bearing various single tyrosine add-back mutant 
CHRD814V receptors. 
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Samples were harvested, fixed in 10% buffered formalin, sectioned and stained with 
hematoxylin and eosin. Shown are representative tissue sections from mice transplanted 
with cells bearing various single tyrosine add-back mutant CHRD814V. Normal 
erythroid and myeloid components in BM, spleen, liver and lungs were replaced b sheets 
of immature tumor cells to various degrees in all the representative animals, but 
predominately in CHRD814V-Y719 (panel 4) followed by CHRD814V-Y745 (panel 6) 
and CHRD814V-Y728 (panel 5), respectively (first row). 
 
 
Differential activation of PI3K, Stat5, and ERK mitogen-activated protein kinase in 
cells bearing various single tyrosine add-back CHRD814V mutant receptors 
To assess the biochemical basis for the differential role of single tyrosine add-
back CHRD814V mutants in ligand independent growth and MPN, activation of AKT, 
Stat5 and ERK, which are known to be critical for KITD814V induced MPN, was 
analyzed (97, 133, 138, 139). As seen in Figure 3.10.A, constitutive phosphorylation of 
AKT, Stat5, and ERK was observed in cells bearing CHRD814V, but not in WT CHR 
bearing cells. Interestingly, loss of seven intracellular tyrosine residues in CHRD814V 
resulted in complete abrogation of the constitutive activation of AKT, Stat5 and ERK 
(Figure 3.10.A, lane 11). Importantly, among the single tyrosine add-back CHRD814V 
mutants, only restoring tyrosine 719 completely rescued the robust constitutive 
phosphorylation of AKT, Stat5, and ERK observed in CHRD814V expressing cells 
(Figure 3.10.A, lane 7). Cells bearing CHRD814V-Y702 and CHRD814V-Y728 showed 
robust activation of AKT and ERK, but not Stat5 (Figure 3.10.A, lanes 6 and 8, 
respectively). Furthermore, a modest constitutive activation of AKT and ERK was 
observed in cells bearing CHRD814V-Y569 (Figure 3.10.A, lane 5). In contrast, no 
activation of AKT, Stat5 and ERK was observed in cells bearing CHRD814V-Y567, 
CHRD814V-Y745 or CHRD814V-Y934 (Figure 3.10.A, lanes 4, 9 and 10, respectively). 
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These results suggest that differential activation of AKT, Stat5 and ERK in cells bearing 
various single tyrosine add-back CHRD814V mutants likely contributes to variable level 
of disease progression and survival of transplanted mice.  
  
Enhanced activation of Stat5, AKT, and ERK by CHRD814V-Y719 
Previous studies of KITD814V have implicated a role in Stat5 and PI3K in 
aberrant signaling in activating mutations of KIT (97). To determine whether 
promiscuous signaling observed in cells bearing KITD814V utilized specific tyrosines for 
SH2 binding molecules we cultured 32D cells expressing the chimeric constructs in the 
absence of growth factor and examined the expression of activated Stat5. As shown in 
Figure 3.10.A, Stat5 was constitutively activated only in cells bearing CHRD814V and 
CHRD814V-Y719 (lane 3 & 7). There was also robust expression of activated AKT and 
ERK in the presence of CHRD814V, CHRD814V-Y719, and CHRD814V-Y702, while 
other single tyrosine add-backs, CHRD814V-Y569 and CHRD814V-Y728, showed 
modest constitutive activation of these molecules. Anti-apoptotic proteins, Bcl-xL and 
Bcl-2 had comparable levels of expression between CHRD814V and CHRD814V-Y719 
(Figure 3.10.B).  
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Figure 3.10. Involvement of AKT, ERK and Stat5 signaling in KITD814V-induced 
ligand-independent growth. 
 
(A) Cells bearing the indicated CHRs were starved in serum-free and growth factor-free 
medium for 8 hours. Starved cells were lysed and equal amount of protein lysates were 
subjected to western blot analysis. Immunoblot using an anti-phospho-Stat5, phospho-
AKT, phospho-ERK, and total Stat3 antibodies as indicated. Similar results were 
observed in two in three independent experiments. (B) Immunoblot for anti-apoptotic 
proteins using anti-Bcl-x, Bcl-2 and -actin. 
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As PI3K plays a crucial role in proliferation and signaling of CHRD814V we 
assessed the binding of p85 to the chimeric receptors through immunoprecipitation.  As 
shown in Figure 3.11, although CHRD814V-F7 does not show binding of p85, 
restoration of tyrosine 719 in the CHRD814V-Y719 is sufficient to restore p85 to 
CHRD814V levels. These observations were further confirmed by binding of KIT to 
p85 in CHRD814V and CHRD814V-Y719 receptors (Figure 3.11.B). Collectively, 
these results demonstrate that tyrosine 719 is necessary and sufficient to restore 
cooperation between KITD814V and the PI3K signaling cascade.  
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Figure 3.11. Intracellular tyrosines on KITD814V are critical for p85 binding. 
 
Cells bearing the indicated CHRs were starved in serum-free and growth factor-free 
medium for 8 hours. Starved cells were lysed and equal amount of protein lysates were 
immunoprecipitated (IP) with (A) anti-KIT or (B) anti-p85 and immunoblotted (IB) 
with anti-KIT or anti-p85.
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3.D CONCLUSIONS 
These studies demonstrate that the direct binding of the ligand SCF to KITD814V 
receptor is not necessary to induce MPN and intracellular tyrosines are critical to this 
process. Mice bearing either the parental KITD814V receptor or the chimeric 
CHRD814V receptor, lacking the ability to bind ligand SCF, show similar potency at 
inducing MPN with similar median survival. Furthermore, no significant difference in 
disease manifestation was observed between the two transplanted groups. Importantly, 
intracellular tyrosines show a critical role in CHRD814V-induced MPN and survival. 
Loss of seven critical tyrosine residues in CHRD814V, which are known to activate 
phospholipase C-γ (728), (70, 140) PI3K (p85α; 719),(141) Src family kinases (567 and 
569), (142-144)  Grb2 (702) (144), Grb7 (934) (144) and Ras GTPase activating protein 
(745) profoundly impaired disease onset and prolonged the survival of transplanted mice. 
Only 70% mice that were transplanted with cells bearing CHRD814V-F7 succumb to 
death with very long latency, while 30% mice were free of disease and survived for the 
remaining duration of the study. Using transduced primary HSC/Ps, we have previously 
demonstrated that KITD814V not only induces ligand-independent growth or responds to 
SCF, but also synergizes with interleukin-3 and M-CSF receptors to further enhance the 
growth of these cells in vitro. This suggests that KITD814V-induced ligand-independent 
growth and its ability to cooperate with other cytokines might also contribute to 
activating KIT-induced MPN(34). Furthermore, KIT has also been shown to cooperate 
with granulocyte M-CSF in a kinase-independent manner (145) and to synergize with 
granulocyte colony-stimulating factor to induce proliferation (146).Therefore, it is 
conceivable that CHRD814V-F7 is not sufficient to induce robust proliferation without 
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growth factor in vitro, but may cooperate with additional cytokine receptors, such as 
interleukin-3, M-CSF and/or granulocyte colony-stimulating factor receptors to induce 
MPN in the 70% transplanted animals in a significantly delayed and milder manner. 
In an effort to assess the role of individual tyrosine-mediated signals in 
KITD814V-induced MPN we employed a unique approach. Although single point 
mutations in important tyrosine residues have been shown to affect KIT function, (147, 
148) we felt that the approach of interfering with the binding of one or two SH2-binding 
proteins to CHRD814V, when all other SH2 proteins still retain the ability to bind may 
not allow for complete assessment of the importance of signals emanating from a single 
pathway, because it is possible that the remaining SH2 consisting proteins may 
compensate for the loss of a single binding site. A single-add back strategy was used to 
assess the role of an individual tyrosine-induced pathway in KITD814V-induced MPN. 
Using a version of the receptor that lacked all seven tyrosines (CHRD814V-F7) as the 
template, we restored each of the SH2-binding sites from phenylalanine to tyrosine and 
tested their ability to induce growth in vitro and transformation in vivo, along with their 
potential to activate downstream signaling molecules known to be involved in 
KITD814V-induced MPN, including AKT, ERK and Stat5. A unique role for tyrosine 
719 in regulating KITD814V-induced MPN was shown that in restoring this site alone in 
the CHRD814V-F7 receptor is sufficient to completely rescue ligand-independent 
growth in vitro, MPN in vivo and activation of AKT, ERK and STAT5, similar to the 
CHRD814V receptor. Importantly, while the remaining add-back mutant receptors 
showed minimal rescue in ligand-independent growth in vitro; in vivo mice bearing these 
receptors demonstrated delayed MPN onset and prolonged latency compared with 
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CHRD814V or CHRD814V-Y719 receptor-bearing mice. These results suggest that 
although ligand-independent growth is sufficient for KITD814V-induced MPN in vivo, 
presence of SCF and other cytokines might further regulate the MPN phenotype. 
The variable onset of MPN and latency in mice transplanted with cells bearing 
various add-back mutant receptors was associated with differential rescue in the 
activation of AKT, ERK and STAT5. In general, add-back CHRD814V mutants that 
lacked the ability to rescue the activation of AKT, ERK and STAT5, such as 
CHRD814V-F7 receptor-bearing mice, demonstrated prolonged latency, while receptors 
demonstrating rescue in the activation of AKT and ERK, such as the CHRD814V-Y702 
receptor-bearing mice, resulted in MPN, albeit at a slower rate. In contrast, receptors that 
robustly activated all three signaling molecules (ERK, AKT and Stat5) such as the 
CHRD814V-Y719 and the CHRD814V receptor, showed the shortest disease latency. 
Thus, KITD814V-induced MPN in vivo is largely dependent on the level of activation of 
AKT, ERK and STAT5, which to a large extent is regulated by signals emanating from 
tyrosine 719, suggesting that signals emanating from tyrosine 719 have a dominant role 
in regulating MPN, while the remaining tyrosine initiated signals contribute to MPN, 
albeit to a lesser extent. Thus, the impairment in the activation of essential signaling 
pathways is likely to contribute to a significant delay in the onset of MPN in mice bearing 
remaining add-back mutants of KITD814V. 
Although studies have suggested that persistent activation of PI3K and Stat5 is 
frequently observed in hematologic malignancies as well as in solid tumors, exactly how 
PI3K contributes to KITD814V-induced MPN and/or Stat5 activation is unclear (149, 
150). We show that tyrosine 719 in KITD814V (binding site for p85α) contributes to the 
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activation Stat5. In cells expressing CHRD814V-F7, no binding of p85α is observed and 
consistently no constitutive activation of Stat5 is observed. Furthermore, deficiency of 
p85α in HSC/Ps expressing KITD814V results in complete inhibition of Stat5 activation 
(151). These results suggest that PI3K-mediated signaling is essential for constitutive 
activation of Stat5 in KITD814V-bearing cells. Taken together, our studies determine the 
contribution of SCF to KITD814V-induced MPN in vivo, and also identify critical 
tyrosine residues and signaling pathways involved in KITD814V-induced MPN. 
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CHAPTER FOUR 
ROLE OF PAK AND RAC GTPASES IN ONCOGENIC KIT INDUCED 
NEOPLASMS 
 
4.A ABSTRACT 
An acquired somatic mutation at codon 816 in the KIT receptor tyrosine kinase is 
associated with poor prognosis in patients with systemic mastocytosis and acute myeloid 
leukemia. Treatment of leukemic cells bearing this mutation with an allosteric inhibitor 
of p21–activated kinase (Pak) or its genetic inactivation results in growth repression due 
to enhanced apoptosis. Inhibition of the upstream effector Rac abrogates the oncogene-
induced growth and activity of Pak. Although both Rac1 and Rac2 are constitutively 
activated via the guanine nucleotide exchange factor (GEF) Vav1, loss of Rac1 or Rac2 
alone moderately corrected the growth of KIT-bearing leukemic cells, whereas the 
combined loss resulted in 75% growth repression. In vivo, the inhibition of Vav or Rac or 
Pak delayed the onset of myeloproliferative neoplasms (MPNs) and corrected the 
associated pathology in mice. To assess the role of Rac GEFs in oncogene-induced 
transformation, we used an inhibitor of Rac, EHop-016, which specifically targets Vav1 
and found that EHop-016 was a potent inhibitor of human and murine leukemic cell 
growth. These studies identify Pak and Rac GTPases, including Vav1, as potential 
therapeutic targets in MPN and AML involving an oncogenic form of KIT. 
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4.B INTRODUCTION 
Previously, we and others have shown that the regulatory subunit of class IA 
PI3K, p85α, is required for KITD814V (murine homolog) induced transformation (97, 
151). Although p85α is a difficult protein to target therapeutically, the downstream 
effectors of the PI3K signaling pathway, in particular guanine exchange factors (GEF) 
such as Vav1, Tiam1 and Trio as well as their downstream targets including Rho family 
GTPases Rac1 and Rac2 and p21-activated kinase (Pak) might contribute to gain-of-
function mutant KIT-mediated transformation.  
Expression of the GEF Vav1 is predominantly restricted to the hematopoietic 
compartment (152). Vav1 consists of multiple domains including calponin homology 
domain, a Dbl homology domain, a pleckstrin homology domain, and a cysteine-rich 
region, as well as a Src homology 2 (SH2) domain flanked by two SH3 domains (153). 
Interestingly, deletion of the N-terminal region of Vav1 alone renders this protein 
oncogenic (152). Although, Vav has been shown to play an important role in regulating T 
and B cell signaling as well as neutrophil functions (113, 154); its role in 
leukemogenesis, in particular in oncogenic KIT induced MPN is unknown. Furthermore, 
in the context of an oncogene such as KITD814V, it is unclear, to what extent Vav1 
regulates the activation of Rac (Rac1 and Rac2) GTPases and to what extent Rac1 and 
Rac2 contribute to transformation either alone or via their downstream substrate such as 
Pak.  
Rac GTPases cycle between inactive GDP-bound and active GTP-bound states. 
Rac2 is predominantly expressed in hematopoietic cells whereas Rac1 is ubiquitously 
expressed (155). Although the role of Rac1 and Rac2 in normal hematopoiesis has been 
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well documented (155); how these GTPases contribute to oncogenic KIT (KITD814V) 
induced transformation is poorly understood. A small molecule antagonist of Rac, 
NSC23766 has been described (156). NSC23766 inhibits the activation of Rac by 
interfering with the binding of GEFs Tiam1 and Trio (156). More recently, Ortiz et al 
described a novel Rac inhibitor, EHop-016, which is derived on the basis of NSC23766’s 
structure and inhibits the activation of Rac with a significantly lower IC50 compared to 
NSC23766 (157). How these two drugs impact the relative growth of KITD814V bearing 
cells and whether they equally inhibit the activation of Rac1 vs. Rac2 in these cells has 
never been explored.  
Paks are serine/threonine kinases (158, 159). As a major downstream effector of 
Rac, Paks play an essential role in regulating both growth and actin based functions (160-
162). Of the three isoforms that belong to group I family, Pak1 is the most well 
characterized member and is ubiquitously expressed (158). Pak1 expression is up-
regulated in several solid tumors including in ovarian, breast and bladder cancers (163-
165). While Pak has been shown to function as a potential downstream target of Rac, its 
relative contribution to MPNs or AML has not been explored. Here, we show that 
KITD814V (mouse) and KITD816V (human) bearing leukemic cells exhibit constitutive 
activation of Pak, Rac GTPases, and GEF Vav1. Utilizing a series of experiments using 
knockout mouse models, mouse models of MPN, dominant negative approaches, an 
allosteric inhibitor of Pak and a novel small molecule inhibitor of Rac, we provide a 
mechanism of KITD814V induced transformation and provide potential novel therapeutic 
targets for treating oncogenic KIT bearing neoplasms. 
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4.C RESULTS 
The guanine exchange factor Vav1 regulates ligand independent growth and Rac1 and 
Rac2 activation in oncogene KIT (KITD814V) bearing cells 
 The role of hematopoietic specific GEF and its downstream substrates including 
Rac1 and/or Rac2 and Pak in KITD814V induced transformation is not known. To assess 
whether KITD814V bearing cells activate the GEF Vav1, we transduced 32D myeloid 
cells lacking the expression of endogenous KIT receptor with a bicistronic retrovirus 
encoding either a wild type (WT) version of KIT or an oncogenic version (KITD814V) 
(166). Transduced cells were sorted to homogeneity on the basis of EGFP expression and 
used in experiments described here. As seen in Figure 4.1.A, transduced cells bearing 
KITD814V following 8 hours of serum and growth factor deprivation demonstrated 
constitutive phosphorylation of Vav1 relative to WT KIT expressing cells. To assess the 
functional significance of constitutive Vav1 phosphorylation in KITD814V bearing 
primary HSC/Ps, we transduced low density bone marrow cells derived from WT or 
Vav1-/- mice with EGFP expressing WT KIT or KITD814V retrovirus. Primary bone 
marrow (BM) cells transduced at similar efficiency were sorted to homogeneity on the 
basis of EGFP expression and subjected to ligand independent (in the absence of stem 
cell factor) growth. As expected and previously shown (166), KITD814V expressing 
HSC/Ps showed a significant increase in ligand independent growth compared to WT 
KIT bearing cells, however, lack of Vav1 in these cells resulted in ~75% repression in 
ligand independent growth (Figure 4.1.B). Loss of Vav2 or Vav3 in primary HSC/Ps did 
not profoundly impact ligand independent growth of KITD814V bearing cells (Figure 
4.2). 
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Figure 4.1. Constitutive activation of GEF Vav1 and Rac-GTPase in KITD814V 
expressing cells. 
 
(A) 32D cells expressing either WT KIT or KITD814V were serum and growth factor 
starved for 8 hours and equal amount of lysates were subjected to IP using an anti-Vav1 
antibody. The position of tyrosine phosphorylated Vav1 is indicated to the right of the 
blot. The right panel indicates the Vav1 protein whole cell lysate loading control. (B) 
Proliferation as assessed by thymidine incorporation in KITD814V expressing WT and 
Vav1 deficient primary BM cells in the absence of growth factors. Bars represent the 
mean thymidine incorporation (in counts per minute) in primary BM cells expressing the 
indicated receptors. Similar results were observed in three independent experiments. *p-
value<0.05, KITD814V vs. Vav1-/- KITD814V. (C) Cell lysates derived in (B) were 
analyzed for Rac-GTP levels by incubating with agarose beads conjugated to Pak binding 
domain and subjecting the IPs to western blot analysis using an anti-Rac1, anti-Rac2 or 
anti-pan Rac antibody. Position of Rac-GTP is indicated to the right of the blot. The 
bottom panel shows total Rac protein in each lane. 
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Figure 4.2. Ligand independent growth of KITD814V bearing cells in the absence of 
Vav2 or Vav3. 
 
Proliferation as assessed by thymidine incorporation in KITD814V expressing WT, 
Vav2, and Vav3 deficient primary HSC/Ps in the absence of growth factors. Bars 
represent the mean [3H] thymidine incorporation (in counts per minute) in primary BM 
cells expressing the indicated receptors. Data are pooled from experiments utilizing BM 
cells from two independent mice of each genotype. 
 
To assess how Vav1 might contribute to KITD814V induced ligand independent 
growth, we determined the activation status of downstream substrates of Vav1, Rac 
family GTPases (155, 167). We examined the activation of both Rac1 and Rac2 in Vav1 
deficient KITD814V bearing HSC/Ps. Figure 4.1.C shows constitutive activation of both 
Rac1 and Rac2 in KITD814V bearing WT HSC/Ps. In contrast, activation of both Rac1 
and Rac2 was reduced in KITD814V bearing Vav1-/- HSC/Ps. These results suggest that 
Vav1 regulates Rac1 and Rac2 activation to similar extent in KITD814V bearing cells 
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and that deficiency of Vav1 in KITD814V bearing cells significantly reduces ligand 
independent growth normally associated with these cells.  
While these results suggest a role for Vav1 in Rac activation and perhaps in 
KITD814V induced transformation; its direct involvement can only be established by 
inhibiting the activation of Rac in these cells. To test this, we infected KITD814V 
bearing 32D myeloid cells with a dominant negative version of Rac (RacN17). A 
bicistronic retrovirus encoding WT KIT or KITD814V along with a human CD4 antigen 
as a selectable marker was employed for these studies (Figure 4.3.A). RacN17 was 
cloned into an EGFP (for selection of transduced cells) encoding retrovirus. 32D myeloid 
cells were co-infected with virus encoding WT KIT or KITD814V and/or RacN17. Cells 
were sorted on the basis of hCD4 and/or EGFP expression (Figure 4.3.A). Single or 
double positive sorted cells were subjected to a proliferation assay. As seen in Figure 
4.3B, expression of a dominant negative version of Rac (RacN17) in KITD814V bearing 
cells significantly repressed ligand independent growth relative to controls. The reduction 
in the growth of KITD814V and RacN17 co-expressing cells was in part due to reduced 
survival relative to controls (Figure 4.3.C). Importantly, IL-3 responses in all these cell 
types including in KITD814V and RacN17 co-expressing cells were comparable (Figure 
4.3.B). The reduction in growth and survival of KITD814V and RacN17 co-expressing 
cells was due to direct repression of Rac1 and Rac2 (Figure 4.3.D). Taken together, these 
results suggest that downstream from Vav1, Rac1 and Rac2 are likely to play an essential 
role in regulating KITD814V induced transformation.  
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Figure 4.3. Inhibition of Rac activity in KITD814V bearing cells suppresses cell 
growth and survival. 
 
(A) Flow cytometric analysis of 32D myeloid cells expressing WT KIT-hCD4 or 
KITD814V-hCD4 (Y-axis) and dominant negative RacN17-EGFP (X-axis). (B) Cells 
expressing KITD814V with or without RacN17 were cultured for 48 hours in the 
presence or absence of IL-3 in replicates of four and subjected to a [3H] thymidine 
incorporation assay. Bars represent the mean ± SD thymidine incorporation (in counts per 
minute). Similar results were observed in three independent experiments. *p-value<0.05, 
KITD814V vs. KITD814V+RacN17. (C) Cells in (B) were grown in the absence of 
growth factors for 24 or 48 hours prior to being subjected to Annexin V and 7-AAD 
staining. Survival (viability) was determined as the percentage of both Annexin V and 7-
AAD negative cells. Bars denote the mean ± SD percentage of total surviving cells from 
one of two independent experiments performed in quadruplicate. *p-value<0.05, 
KITD814V vs. KITD814V+RacN17. (D) Cells in (B) were subjected to Pak binding 
domain (PBD) pull down assay to assess Rac1-GTP, Rac2-GTP, total Rac1 and total 
Rac2 expression in the indicated genotypes. Data are from a representative experiment 
performed on 3 independent occasions. 
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To test this in more detail, we performed transplant studies by injecting myeloid 
cells co-expressing KITD814V and RacN17 along with control cells into C3H/HeJ 
syngeneic mice (166). Transplanted mice were observed for the development of MPN 
and survival relative to controls. Mice transplanted with cells co-expressing KITD814V 
and RacN17 demonstrated a significantly prolonged lifespan relative to KITD814V only 
expressing mice (Figure 4.4.A). A cohort of KITD814V and RacN17 co-expressing mice 
were analyzed in detail at the same time as when KITD814V only bearing mice first 
began to succumb, to assess the impact of Rac repression on MPN development. As seen 
in Figure 4.4.B, KITD814V bearing mice showed PB counts in the range of 150 K/μl. In 
contrast, mice transplanted with cells co-expressing KITD814V and RacN17 
demonstrated a profound reduction in PB WBCs and neutrophils counts. Additional 
analysis was conducted on KITD814V and RacN17 co-expressing mice when KITD814V 
only mice began to succumb. In other words, KITD814V and RacN17 bearing mice were 
sacrificed at the same time as moribund KITD814V mice to assess disease progression 
and the impact of Rac repression on MPN. Around the time of death, up to 90% leukemic 
cells were detected in the PB, BM and spleen of mice transplanted with cells bearing 
KITD814V alone (Figure 4.5.A). In contrast, mice transplanted with cells co-expressing 
KITD814V and RacN17 demonstrated only ~20% leukemic cells as determined by EGFP 
positivity in all three tissues examined. Figure 4.5.A left panel shows quantitative 
assessment of the presence of EGFP expressing cells in PB, BM and spleen; and right 
panel demonstrates representative flow cytometry blots demonstrating the percentage of 
EGFP expression in various tissues in the indicated genotypes. Figure 4.5.B demonstrates 
a quantitative reduction in the spleen weight of mice transplanted with cells co-
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expressing KITD814V and RacN17 relative to mice transplanted with cells bearing the 
KITD814V mutation alone. Right panel depicts representative spleens derived from 
KITD814V bearing mice as well as mice co-expressing both KITD814V and RacN17. 
Importantly, while gross lung lesions were observed in mice transplanted with cells 
bearing KITD814V alone; these lesions were nearly absent in the lungs of transplanted 
mice co-expressing KITD814V and RacN17 (Figure 4.5.C). Histopathological analysis 
revealed that while massive myeloid cell infiltration was observed in mice transplanted 
with KITD814V bearing cells in spleen and lungs; mice bearing cells co-expressing 
KITD814V and RacN17 showed significantly less infiltration of these cells and the 
splenic architecture in these mice was indistinguishable from control mice (Figure 4.4.C-
D).  
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Figure 4.4. In vivo inhibition of Rac prolongs the survival and rescues myeloid cell 
infiltration associated with KITD814V bearing mice. 
 
C3H/HeJ mice were transplanted with 2 million cells bearing KITD814V with or without 
RacN17. (A) Kaplan-Meier survival analysis of syngeneic C3H/HeJ mice transplanted 
with cells bearing KITD814V (n=16) or KITD814V+RacN17 (n=26). *p-value<0.001, 
KITD814V vs. KITD814V+RacN17. (B) White blood cell (WBC) and neutrophil (NE) 
counts in mice bearing cells transplanted with KITD814V (n=9) or KITD814V+RacN17 
(n=12) and C3H/HeJ control mice (n=5). *p-value<0.05, KITD814V vs. 
KITD814V+RacN17.  Histopathologic analysis of spleen (C) and lung (D) from mice 
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transplanted with cells bearing KITD814V alone or in combination with RacN17. Shown 
are representative tissue sections (10 to 40 X magnifications) after fixing them in 10% 
buffered formalin, sectioning and staining with hematoxylin and eosin. Normal erythroid 
and myeloid components in lungs, liver and spleen were replaced by leukemic cells in 
KITD814V bearing mice, which were significantly rescued in tissues from mice bearing 
RacN17 along with KITD814V. (E) Cell lysates derived from spleens of mice described 
above were subjected to a Rac activity assay as described in Figure 4.1.C. Shown is the 
level of Rac1-GTP, Rac2-GTP, total Rac1, and total Rac2 in each lane from the indicated 
genotypes. 
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Figure 4.5. Inhibition of Rac rescues the tissue damage associated with mice 
transplanted with cells bearing KITD814V. 
 
(A) Left panel shows the percentage of EGFP+ leukemic cells in the peripheral blood, 
bone marrow, and spleen of mice transplanted with cells bearing KITD814V alone or in 
combination with RacN17 at the time of moribund. n=5, *p-value<0.001, KITD814V vs. 
KITD814V+RacN17. Right panel shows representative flow cytometric dot blot profiles 
from mice described in left panel at time of moribund. (B) Weight and size of spleens 
from various genotypes was assessed at time of moribund. Quantitative differences in the 
weight of spleens from the indicated genotypes are shown in the left panel and 
representative pictures of spleens are shown in the right panel. n=5, *p-value<0.001, 
KITD814V vs. KITD814V+RacN17. (C) Representative pictures of liver from mice 
transplanted with cells bearing KITD814V alone or in combination with RacN17.  
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To assess whether the enhanced survival of mice, reduced infiltration of myeloid 
blasts in various tissues, including lung and liver and lack of destruction of the splenic 
architecture observed in mice transplanted with cells co-expressing KITD814V and 
RacN17 was due to reduced Rac activation, we examined the activation status of Rac1 
and Rac2 in splenocytes derived from the indicated genotypes. Cellular lysates from 
spleens of KITD814V bearing mice were harvested at moribund. At the same time, 
splenic lysates were derived from mice transplanted with cells co-expressing KITD814V 
and RacN17, designated as time point matched and at moribund, respectively. As seen in 
Figure 4.4.E, mice transplanted with cells co-expressing RacN17 and KITD814V showed 
significant repression in the activation of both Rac1 and Rac2 compared to controls. In 
addition to Rac repression, a significant repression in the activation of Pak, a downstream 
substrate of Rac was also observed (Figure 4.6). These results suggest that expression of 
RacN17 in KITD814V bearing cells likely inhibits their growth in vivo by inhibiting the 
activation of Rac1 and Rac2, resulting in prolonged survival and delayed MPN 
development.  
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Figure 4.6. In vivo reduction of active Pak due to Rac inhibition in KITD814V 
bearing mice.  
 
Cell lysates derived from spleens of C3H/HeJ mice transplanted with cells bearing 
KITD814V with or without RacN17 were immunoblotted with antibodies that recognize 
phospho-Pak and total Pak. 
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Figure 4.7.  Inhibition of Rac GTPases affects KITD814V growth due to increased 
apoptosis. 
 
(A) 32D cells bearing WT KIT grown in the presence of 5ng/mL IL-3 or KITD814V 
bearing cells grown in the absence of growth factors and indicated Rac inhibitor 
(NSC23766) were subjected to a [3H] thymidine incorporation assay. (B) Murine 
mastocytoma cells, P815, and (C) human AML patient derived Kasumi-1 cells were 
cultured in the presence of NSC23766 and assessed for proliferation by measuring [3H] 
thymidine incorporation. Bars represent mean ± SD from 2 to 4 independent experiments 
performed in replicates of four. *p-value<0.05. (D) 32D cells expressing KITD814V or 
WT KIT cells grown in the presence of a novel Rac inhibitor, EHop-016, were subjected 
to a [3H] thymidine incorporation assay as described above. *p-value<0.05 (E) 
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KITD814V bearing 32D cells were examined for survival in the presence of 5µM or 
10µM EHop-016 for 0, 24, or 48 hours prior to subjecting the cells to Annexin V and 7-
AAD staining. Survival was assessed by quantitating the percentage of Annexin V and 7-
AAD negative (viable) cells. Bars denote the mean ± SD percentage of viable cells from 
one of two independent experiments performed in quadruplicate. *p-value<0.05, vehicle 
vs EHop-016 treated.  (F) Cells described in (E) were treated with EHop-016 and cell 
lysates were subjected to immunoblotting with phospho-MLC, phospho-BAD, and -
actin.  
 
Growth of oncogenic KIT (KITD814V in mouse and KITD816V in humans) bearing 
murine and human mastocytosis patient derived cells is inhibited by a novel Rac 
inhibitor, EHop-016 
Based on the observation that Rac inhibition in vivo delays KITD814V driven 
MPN, we hypothesized that pharmacologic inhibition of Rac might inhibit KITD814V 
induced proliferation in vitro. For these studies, we first utilized a well characterized Rac 
inhibitor NSC23766 (156). NSC23766 inhibits Rac binding and activation by the Rac 
specific GEF Trio or Tiam1 (156). Treatment of myeloid cells bearing the WT KIT or 
KITD814V receptor with NSC23766 demonstrated a dose dependent reduction in 
hyperproliferation of KITD814V bearing cells but not of WT KIT bearing cells (Figure 
4.7.A). Consistently, treatment of a murine mastocytoma cell line P815 that bears the 
activating KITD814V mutation, as well as AML patient derived Kasumi-1 cells, that 
expresses the KITD816V mutation, demonstrated a dose dependent growth repression in 
the presence of NSC23766 (Figure 4.7.B & C). While a dose dependent growth inhibition 
of oncogene KIT bearing cells in the presence of NSC23766 was observed; the 
concentration of NSC23766 that resulted in 50% growth inhibition of leukemic cells was 
nearly 75 to100 µM for all cell types examined. This could potentially be due to a lack of 
a major role of GEFs Trio and Tiam1 in KITD814V induced transformation. 
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Alternatively, Rac1 and/or Rac2 alone may play only a modest role in KITD814V 
induced transformation. To test these possibilities and to more precisely identify the 
consequence(s) of interfering with the function of GEFs and Rac in KITD814V induced 
transformation, we utilized a novel Rac inhibitor EHop-016, which is a derivative of 
NSC23766 and inhibits Rac 100-fold more efficiently than NSC23766 in metastatic 
breast cell line, MDA-MB-231 (157). As seen in Figure 4.8.A & B, KITD816V bearing 
SM human patient derived HMC1.2 cells, as well as KITD816V and AML1-ETO bearing 
Kasumi-1 cells derived from an AML patient, demonstrated a significant reduction in the 
growth of these cells in the presence of EHop-016 at drug concentrations that were 
significantly less (~50-fold in some cases) than NSC23766, IC50=100 µM.  Importantly, 
primary systemic mastocytosis patient derived cells bearing KITD816V were 
significantly more susceptible to growth inhibition in the presence of EHop-016 relative 
to patient samples lacking the expression of KITD816V (Figure 4.8.C). The growth 
reduction in the presence of EHop-016 was also observed in murine KITD814V 
expressing cells and was associated with enhanced apoptosis and repression of anti-
apoptotic proteins Bad and MLC (Figure. 4.7.D-F). Consistent with these findings, while 
20µM of NSC23766 inhibited the activation of Rac1 but not Rac2 in KITD814V bearing 
cells; 10µM of EHop-016 was sufficient to inhibit the activation of both Rac1 and Rac2 
in these same cells, which was associated with reduced binding of Vav for Rac (Figure 
4.8.D & 4.8.E). These results suggest that inhibition of both Rac1 and Rac2 is essential 
for maximal growth repression in KITD814V bearing cells. Further, Rac inhibitor EHop-
016 is significantly more efficient in repressing the growth and activation of Rac1 and 
Rac2 in KITD814V bearing cells compared to NSC23766. Consistent with the in vitro 
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findings described above, treatment of KITD814V bearing cells with EHop-016 vs. 
NSC23766 significantly enhances the survival of leukemic mice, which is associated with 
reduced spleen size and PB counts (Figure 4.9.A-D). 
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(A) Human SM patient derived HMC1.2 cells bearing KITD816V and (B) human AML 
derived Kasumi-1 cells bearing KITD816V were cultured in the presence of EHop-016 
and assessed for proliferation by measuring [3H] thymidine incorporation. Bars represent 
mean ± SD from 4 independent experiments performed in replicates of four. *p-
value<0.05 (C) Individual systemic mastocytosis patient derived cells positive or 
negative for KITD816V expression were cultured in the presence of indicated 
concentrations of EHop-016. Bars represent mean ± SD performed in replicates of three. 
*p-value<0.05, 0µM vs indicated concentration. (D) 32D cells bearing WT KIT or 
KITD814V were starved and treated with indicated concentrations of NSC23766 or 
EHop-016 and subjected to Rac activation assay. Shown are the levels of active Rac1, 
Rac2, total Rac1, and Rac2 in each lane. (E) 32D cells expressing either WT KIT or 
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Figure 4.8. A novel Rac inhibitor, EHop-016, is a potent inhibitor of KITD814V 
induced growth in systemic mastocytosis (SM) and AML patient derived cells. 
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KITD814V were starved and incubated with vehicle, 5 or 10µM EHop-016; lysates were 
immunoprecipitated (IP) with anti-Rac1 antibody and immunoblotted with an anti-Vav1 
or an anti-Rac1 antibody, respectively. The lower panels indicate the Vav1 and Rac1 
protein whole cell lysate loading control. 
 
 
 
Figure 4.9. Pharmacologic inhibition of Rac GTPases delays disease progression in 
mice transplanted with cells bearing KITD814V receptor. 
 
C3H/HeJ mice were transplanted with 1 million cells bearing KITD814V following 
overnight in vitro treatment with vehicle (n=6), EHop-016 (2.5 µM, n=7), or NSC23766 
(25 µM, n=7) and (A) survival was analyzed by Kaplan-Meier rank log analysis. *p-
value<0.05 Vehicle vs EHop-016 or NSC23766. (B) Peripheral blood counts for white 
blood cells (WBC), and neutrophils (NE) between the different transplanted groups at 
time of harvest. *p-value<0.05, Vehicle vs EHop-016. (C)  Quantitative difference in 
spleen mass and (D) representative spleens from indicated transplantation groups are 
shown. *p-value<0.05, Vehicle vs. EHop-016. 
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Genetic disruption of Rac GTPases in KITD814V bearing HSC/Ps inhibits ligand 
independent hyperproliferation and MPN in vivo   
We next analyzed the specific role of Rac1 and Rac2 and also attempted to 
confirm our findings using dominant negative Rac (RacN17) and pharmacologic 
approaches by examining the growth of KITD814V bearing primary BM cells derived 
from mice lacking the expression of Rac1, Rac2 or both Rac1 and Rac2. Since complete 
loss of Rac1 results in embryonic lethality, conditional knockout strain of Rac1 was 
crossed with Mx1-Cre mice allowing for conditional deletion of Rac1 in BM cells. To 
induce Cre recombinase expression, three doses of 200µg polyI:polyC were injected 
intraperitoneally at forty-eight hour intervals. As seen in Figure 4.10.A, and has been 
previously described, conditional deletion of Rac1 results in loss of Rac1 protein (111).  
Conditional Rac1 mice were crossed with Rac2 transgenic knockout mice and following 
polyI:polyC treatment a similar loss of Rac1 protein was also observed in mice lacking 
both Rac1 and Rac2 as assessed by western blot analysis using a Rac1 specific antibody 
(Figure 4.10.A; lanes 2 & 4). Low density BM cells from all three genotypes were pre-
stimulated with cytokines and infected with a retrovirus expressing WT KIT or 
KITD814V. Figure 4.10.B shows the transduction efficiency of the two viruses in BM 
cells derived from different genotypes. Transduced cells were sorted to homogeneity and 
utilized in a proliferation assay as well as to assess survival in the absence of Rac 
proteins. As seen in Figure 4.10.C, while loss of Rac2 resulted in ~50% inhibition in 
ligand independent growth of KITD814V bearing cells; loss of Rac1 showed only a 
modest reduction (~10 to 15%) in ligand independent growth. In contrast, BM cells 
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deficient in both Rac1 and Rac2, showed a more profound reduction in the growth of 
KITD814V bearing cells (~75%).  
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Figure 4.10. Deficiency of Rac1 and Rac2 in KITD814V bearing primary HSC/Ps 
represses ligand independent growth. 
 
(A) Peripheral blood cells were collected from WT, Rac1 flox/flox, Rac2-/- and Rac2-/-
:Cre:Rac1 flox/flox mice following four consecutive intraperitoneal injections of 
polyI:polyC given at 48 hour intervals. Red blood cells were lysed, and equal amount of 
protein were subjected to western blotting using an anti-Rac1 antibody. Levels of Rac1 in 
each lane are shown. (B) Representative flow cytometric dot plots of low density bone 
marrow cells derived from WT, Rac1-/-, Rac2-/- and Rac1-/-:Rac2-/- mice transduced 
with WT KIT or KITD814V expressing retrovirus. EGFP expression on X-axis is 
reflective of the transduction efficiency in the indicated genotypes.  (C) WT, Rac1-/-, 
Rac2-/- and Rac1-/-:Rac2-/- primary HSC/Ps expressing WT KIT or KITD814V were 
subjected to a thymidine incorporation assay. *p-value<0.05, KITD814V in WT vs. 
Rac2-/-, Rac1-/- or Rac1-/-:Rac2-/- cells. Combined data from three independent 
experiments in replicates of four is shown. (D) WT, Rac1-/- and Rac1-/-:Rac2-/- primary 
HSC/Ps expressing KITD814V were grown in the absence of growth factors for 0, 24 or 
48 hours prior to being analyzed by Annexin V and 7-AAD staining. Apoptosis was 
determined as percentage of both Annexin V and 7-AAD positive staining. Bars denote 
the mean ± SD percentage of Annexin V and 7-AAD negative (viable) cells. *p-
value<0.05, WT, Rac1-/- vs. Rac1-/-:Rac2-/-. 
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The reduction in the growth of Rac1/Rac2 double knockout cells bearing KITD814V was 
due in part to reduced survival of cells relative to controls (Figure 4.10.D).  These 
findings suggest that combined loss of Rac1 and Rac2 results in most growth repression 
in KITD814V bearing cells. Restoring the expression of activated Rac in the setting of 
Rac1/Rac2 deficiency rescued ligand independent growth in vitro (Figure 4.11.A). 
Furthermore, no compensatory increase in the expression of Rac3 was noted in these cells 
(Figure 4.11.B). To further assess the role of Vav1 and Rac1/Rac2 in KITD814V induced 
MPN, we infected WT or Vav1-/-  or Rac1/Rac2-/- 5-FU treated BM cells with a virus 
expressing WT KIT or KITD814V, sorted the cells on the basis of EGFP expression and 
transplanted into lethally irradiated hosts. Figure 4.12 shows the transduction efficiency 
in 5-FU treated cells of all three genotypes.  As seen in Figure 4.13.A, a significant 
increase in the survival of mice bearing Vav1-/- or Rac1/Rac2-/-KITD814V expressing 
cells was observed relative to controls. Further, a rescue in the peripheral blood counts 
and splenomegaly in these mice relative to controls was also observed (Figure 4.13.B-D). 
Loss of Rac2 alone in the setting of KITD814V expression also prolonged the survival of 
leukemic mice but to a much lesser degree compared to mice transplanted with 
KITD814V bearing cells lacking the expression of Vav1 or Rac1/Rac2 (Figure 4.14). 
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Figure 4.11. Expression of active RacV12 restores KITD814V induced 
hyperproliferation in Rac1/Rac2 deficient HSC/Ps. 
 
(A) Primary HSC/Ps were collected from WT and MxCreRac1flox/floxRac2-/- mice 
following three consecutive intraperitoneal injections of polyI:polyC given at 48 hour 
intervals. These cells were transduced with KITD814V in the presence of empty vector or 
RacV12, sorted on EGFP and selected in puromycin and assessed for proliferation by 
[3H] thymidine incorporation in the absence of growth factors. Bars represent the mean 
[3H] thymidine incorporation (in counts per minute) in primary HSC/Ps expressing the 
indicated receptors. *p-value<0.05, empty vector vs RacV12. (B) KITD814V bearing 
WT or Rac1-/-:Rac2-/- HSC/Ps were lysed, and equal amount of lysates were subjected 
to western blotting using total Rac1, Rac2, pan-Rac, and ß actin antibody.  
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Figure 4.12. Transduction efficiency of primary 5-FU treated bone marrow (BM) 
cells. 
 
5-fluorouracil treated BM cells derived from WT, Vav1-/-, and Rac1flox/floxRac2-/- mice 
were infected with retrovirus encoding the KITD814V receptor. EGFP expression on the 
x-axis is indicative of the transduction efficiency for each genotype. Transduced cells 
were sorted to homogeneity prior to being transplanted into recipients for MPN 
development and survival studies described in Figure 4.13. 
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Figure 4.13. Genetic disruption of GEF Vav1 and Rac GTPases enhances the 
survival of KITD814V bearing mice. 
 
(A) Cumulative survival analysis using Kaplan-Meier log-rank test of recipient mice 
bearing KITD814V expressing wild type (WT; n=10), Vav1-/- (n=5), or Rac1-/-;Rac2-/- 
(n=5) HSC/Ps. *p-value<0.05 WT vs Vav1-/- or Rac1-/-/Rac2-/-. (B) Peripheral blood 
counts were significantly elevated in recipients of KITD814V bearing WT HSC/Ps 
(n=10) relative to KITD814V bearing Vav1-/- (n=5), or Rac1-/-;Rac2-/- (n=5) HSC/Ps. *p-
value<0.05 for WT  vs Vav1-/- or Rac1-/-;Rac2-/-: KITD814V. Data are mean ± SEM. (C) 
Quantitative difference in the size of the spleen and liver between different transplanted 
groups. *p-value<0.05. WT vs Vav1-/- or Rac1-/-/Rac2-/-. (D) Representative spleen 
pictures derived from mice transplanted with HSC/Ps bearing KITD814V in the setting of 
the indicated genotypes.  
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Figure 4.14. Genetic disruption of Rac2 enhances survival of KITD814V bearing 
mice. 
 
Cumulative survival using Kaplan-Meier log-rank test of recipient cohorts bearing 
KITD814V expressing wild type (WT; n=11) (97) or Rac2-/- (n=10) BM. *p-value<0.05. 
Data showing the survival of KITD814V bearing mice has been previously shown (97).  
 
Role of p21-activated kinase in KITD814V induced transformation  
As noted earlier, expression of dominant negative Rac (RacN17) in KITD814V 
bearing cells derived from the spleens of transplanted mice, not only resulted in reduced 
Rac1/Rac2 activation but also inhibited the activation of Pak. Paks involvement in MPNs 
or in leukemogenesis has never been reported, although recent studies have implicated 
Pak in regulating the growth and actin based functions in solid tumors (168-170). To 
assess the role of Pak in KITD814V induced transformation and to determine if Pak 
functions downstream from Vav1 and Rac1/Rac2 in KITD814V bearing cells, we 
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examined Pak activation in KITD814V bearing Vav1-/-, Rac1/Rac2-/-, RacN17 or EHop-
016 treated primary HSC/Ps. As seen in Figure 4.15.A-D, a reduction in the activation of 
Pak was observed in every scenario. To assess Paks role directly in regulating ligand 
independent growth of KITD814V bearing cells, we utilized myeloid cells bearing the 
expression of KITD814V and infected them with a retrovirus expressing a dominant 
negative version of Pak (PakK299R). 100% EGFP (reflecting the expression of 
PakK299R) and hCD4 (reflecting the expression of KITD814V) double positive cells 
were sorted to homogeneity and subjected to a biochemical and proliferation assay as 
described in Figure 4.2 (Figure 4.16.A). As seen in Figure 4.15.E, while expression of 
KIT and its constitutive phosphorylation was observed in both KITD814V and 
KITD814V and PakK299R co-expressing cells, activation of Pak was completely 
inhibited in cells co-expressing KITD814V and PakK299R relative to controls. 
Importantly, Pak repression in KITD814V bearing cells completely abrogated ligand 
independent proliferation normally observed in KITD814V bearing cells but not of cells 
stimulated via the IL-3 signaling pathway (Figure 4.15.F). Expression of an activated 
version of Pak (PakT423) in Rac1/Rac2 deficient KITD814V bearing primary HSC/Ps 
rescued ligand independent growth (Figure 4.16.B). 
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Figure 4.15.  KITD814V induces the activation of Pak in a Vav1 and Rac dependent 
manner. 
 
KITD814V expressing WT or Rac1/Rac2 (A) or Vav1 (B) deficient primary HSC/Ps 
from two independent animals were starved and lysed and immunoblotted for active Pak.  
(C) KITD814V bearing 32D cells expressing RacN17 were starved, lysed and equal 
amounts of lysates were subjected to immunoblotting using a phospho-Pak antibody and 
total Pak. (D) Cells bearing WT KIT or KITD814V were starved and treated with 
indicated concentrations of NSC23766 or EHop-016 and subjected to Rac activation 
assay. Shown are the levels of phosphorylated and total Pak. (E) 32D cells were 
transduced with KITD814V with or without dominant negative PakK299R and starved, 
lysates were subjected to western blot analysis using a phospho-KIT, phospho-Pak, total 
KIT, total Pak and total ERK antibodies. (F) Cells in (E) were starved for 6 hours before 
being plated in quadruplicate in the presence or absence of growth factors (IL-3, 5ng/ml) 
for 48 hours. Cells were pulsed with [3H] thymidine for 6 hours and harvested. Bars 
denote the mean thymidine incorporation (cpm ± SD) from one of four independent 
experiments performed in quadruplicate. *p-value<0.05, KITD814V vs. KITD814V plus 
PakK299R. 
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Figure 4.16. Activated Pak in the absence of Rac GTPases rescues 
hyperproliferation in primary LDMNCs bearing KITD814V. 
 
 (A) 32D cells were transduced with KITD814V with or without dominant negative 
PakK299R. Flow cytometric dot plot profiles from a representative experiment are 
shown. (B) Primary HSC/Ps from WT and MxCreRac1flox/floxRac2-/- mice were harvested 
following three consecutive intraperitoneal injections of polyI:polyC given at 48 hour 
intervals. These cells were transduced with KITD814V in the presence of empty vector or 
PakT423 and assessed for growth by thymidine incorporation in the absence of growth 
factors. Bars represent the mean thymidine incorporation (in counts per minute) in 
primary HSC/Ps expressing the indicated receptors. *p-value<0.05, empty vector vs 
PakT423. 
 
 
A
0
10000
20000
30000
40000
WT: KITD814V-Vector
Rac1-/-/Rac2-/-: KITD814V-Vector
Rac1-/-/Rac2-/-: KITD814V-PakT423E
*
B
100 
 
 
Figure 4.17. Inhibition of constitutively active Pak by IPA-3. 
 
 (A) KITD814V bearing murine mastocytoma cells P815 were incubated in the presence 
or absence of 10M IPA-3 and subjected to immunoblotting with phospho-Pak antibody. 
Levels of phospho-Pak and total protein in each lane are shown. HMC1.2 (B), P815 (C) 
and Kasumi-1(D) cells bearing an activating KIT mutation exhibited dose dependent 
inhibition when grown in the presence of IPA-3 and assessed for proliferation by 
measuring [3H] thymidine incorporation. Bars represent mean ± SD from 2 to 3 
independent experiments performed in replicates of three. *p-value<0.05. (E) P815 cells 
were subjected to an apoptosis assay after treating them with 10 or 15µM IPA-3 under no 
growth factor conditions for 24, or 48 hours prior to analyzing them by Annexin V and 7-
AAD staining. Apoptosis was assessed as percentage of Annexin V and 7-AAD positive 
cells.  Bars denote the mean ± SD percentage of total viable cells from one of two 
independent experiments performed in quadruplicate. *p-value<0.05, 0µM vs.10 or 
15µM.  
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We next assessed the consequence of pharmacologic inhibition of Pak on the 
growth of KITD814V bearing cells using a cell permeable allosteric inhibitor of Pak, 
IPA-3 (171). As seen in Figure 4.17.A, treatment of KITD814V bearing P815 cells with 
IPA-3 resulted in inhibition of Pak activation and treatment of HMC1.2 cells, P815 cells 
and Kasumi-1 cells with the same inhibitor led to a dose dependent inhibition in the 
growth of KITD816V and KITD814V-bearing cells, respectively with IC50 of 10-15 µM 
(Figure 4.17.B-D). Repression in the growth of oncogene KIT bearing cells in the 
presence of IPA-3 was largely due to reduced survival (Figure 4.17.E).  
To directly assess the impact of Pak inhibition on KITD814V induced MPN 
development, we transplanted C3H/HeJ mice with cells bearing KITD814V and 
PakK299R as described (166). Transplanted mice were observed for the development of 
MPN and survival. Although all KITD814V bearing mice die by day 15 post-
transplantation; all KITD814V and PakK299R co-expressing mice survived this period 
and showed a significant delay in disease onset (Figure 4.18.A). To assess the changes in 
tissue pathology in mice bearing cells co-expressing KITD814V and PakK299R with 
those bearing only KITD814V, we sacrificed a cohort of mice on days when KITD814V 
only bearing mice succumb to death. As seen in Figure 4.18.B and 4.18.C, compared to 
KITD814V bearing control mice, mice co-expressing KITD814V and PakK299R 
demonstrated a significantly lower spleen weights and peripheral blood counts. In 
addition, these mice demonstrated a significant correction in splenic architecture (Figure 
4.18.E), myeloid cell infiltration in the lung (Figure 4.18.D) and liver (Figure 4.18.F) as 
well as lacked lesions on lungs normally associated with KITD814V bearing mice 
(Figure 4.18.G). All of these findings were associated with reduced percentage (as 
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assessed by EGFP expressing cells) of leukemic cells in tissues of mice transplanted with 
cells bearing KITD814V and PakK299R (Figure 4.18.H).  
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Figure 4.18. Inhibition of Pak in vivo in KITD814V bearing mice enhances the 
survival and significantly delays development of MPN. 
 
(A) Kaplan-Meier survival curves of mouse cohorts transplanted with either 32D cells 
bearing KITD814V alone or in combination with PakK299R. Survival of recipients with 
PakK299R was significantly prolonged compared to KITD814V alone transplanted mice 
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(n=3 to 4; *p-value<0.01). Repression of Pak in vivo in KITD814V bearing cells results 
in significant lower spleen weights (B) and peripheral blood counts (C) relative to 
controls. n=3, *p-value<0.05. (D), (E) & (F) lungs, spleens and livers from the indicated 
genotypes were subjected to histopathological analysis. Shown are representative tissue 
sections at 10 to 40X magnification. (G) Representative pictures of intact lungs from 
mice bearing KITD814V alone or in combination with PakK299R. (H) Percentage of 
EGFP+ leukemic cells in mice bearing KITD814V or KITD814V in combination with 
PakK299R. Quantitative assessment of EGFP positive cells (n=3, *p-value<0.05).
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4.D CONCLUSIONS 
Rac and its downstream effector Pak are frequently overexpressed and/or 
hyperactive in solid cancers including in breast cancer (104). In these cells, Rac and Pak 
have been implicated in regulating invasion and metastasis (172, 173). While significant 
progress has been made in our understanding of the role of these molecules in solid 
cancers; how these molecules regulate oncogene induced MPN is poorly understood. We 
provide in vitro and in vivo genetic, biochemical, as well as pharmacologic evidence to 
suggest that the Vav/Rac/Pak pathway plays an essential role in regulating transformation 
via an oncogenic form of KIT (KITD814V) associated with MPN and AML and for 
which no efficacious therapies are currently available. While gain of function KIT 
mutations localized to the juxtamembrane region associated with GISTs are highly 
sensitive to inhibition by imatinib, KIT mutations within the second catalytic domain 
found in patients with AML and SM, including KITD814V, interfere with the binding of 
imatinib, thus rendering this mutation insensitive to imatinib inhibition (83, 136, 174). 
Our results suggest that inhibition of constitutively active Vav, Rac or Pak downstream 
from KITD814V is a highly efficient alternative approach for treating hematologic 
malignancies involving this mutation. 
To date, several GEFs for Rac have been identified (175, 176); however, GEFs 
such as those that belong to the Vav family as well as Tiam-1 have been primarily 
implicated in tumorgenesis (177-179). Although, the precise mechanism(s) by which 
these GEFs regulate cancer progression is still unclear; studies suggest that Vav GEFs are 
significantly more diverse in their ability to activate Rho family GTPases and can 
regulate the activation of Rac, Rho and Cdc42, compared to Tiam-1 and Trio, which 
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primarily activate Rac (156, 180-182). While it is unclear how this occurs, presence of 
Src homology and cysteine rich domains in Vav are likely to contribute to this diversity. 
Our findings utilizing HSC/Ps derived from Vav1 deficient mice engineered to express 
KITD814V suggest an essential role for Vav1 in regulating ligand independent growth of 
oncogene bearing cells as well as activation of both Rac1 and Rac2.   
Our findings demonstrating correction of myeloid cell infiltration in the lungs of 
mice co-expressing RacN17 or PakK299R along with KITD814V, suggests that 
KITD814V induced metastasis of myeloid cells in these tissues is dependent on Rac and 
Pak. Furthermore, our results also demonstrate that prolonged survival of KITD814V 
bearing mice in the setting of RacN17 expression correlates with significant repression of 
Rac1, Rac2 and Pak in these cells and loss of Rac1, Rac2 or both Rac1 and Rac2 
significantly represses ligand independent growth in these cells. These findings were also 
confirmed by utilizing mice bearing KITD814V in the setting of Vav1 and Rac1/Rac2 
deficiency and transplanted into lethally irradiated WT recipients. Interestingly, our data 
implicating Rac1 and Rac2 in KITD814V induced transformation are similar to those 
reported by Thomas et al using the p210BCR-ABL translocation (183). In both instances, 
Rac1 and Rac2 deficiency collectively shows a more prolonged survival of leukemic 
mice.   
In addition to the genetic approaches to test the role of Rac in MPN, we also 
employed pharmacologic approaches to test the possibility of targeting Rac GTPases for 
the treatment of KITD814V induced MPN and AML. To this end, we first utilized an 
established Rac inhibitor, NSC23766. Previous studies have shown that NSC23766 
functions by binding in the pocket of Rac1 that interact with GEFs such as Trio and 
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Tiam1 but not Vav (156, 184). Our results using this drug suggest that Rac1 does not 
significantly contribute to KITD814V induced transformation as we see only 50% 
reduction in the growth of both murine and human oncogene KIT bearing cells at very 
high doses of NSC23766. While reasonable, an alternate explanation may involve a lack 
of robust involvement of Trio and Tiam1 in KITD814V induced transformation. 
Therefore, in an effort to assess if Rac GTPase could be targeted more efficiently in KIT 
oncogene bearing cells, we utilized a newly described Rac inhibitor, EHop-016 (157). 
This drug is a derivative of NSC23766 and inhibits Rac 100-fold more efficiently relative 
to the parental compound (157). EHop-016 like NSC23766 binds to the surface groove of 
Rac, which is critical for interacting with GEFs. Studies have shown that EHop-016 is 
more potent than the parental compound in terms of its interaction with the effector 
domains of Rac (157). This presumably allows EHop-016 to block the activation of 
additional Rac-GEFs in addition to those blocked by NSC23766. Our head to head 
studies comparing NSC23766 and EHop-016 show that EHop-016 is a more potent Rac 
inhibitor than NSC23766. 
Although we have no direct evidence to suggest which additional GEFs might be 
inhibited by EHop-016 in oncogene KIT bearing cells, previous studies in MDA-MB-435 
metastatic breast cancer line has shown that EHop-016 inhibits the interaction of Vav2 
with Rac (157). It is therefore likely that in KITD814V bearing HSC/Ps, EHop-016 
inhibits the interaction of Vav1 with Rac1 and Rac2. We show that treatment of 
oncogene bearing cells with EHop-016 results in inhibition of both Rac1 and Rac2. 
Consistent with these findings, deficiency of Vav1 in oncogene bearing cells impairs the 
activation of both Rac1 and Rac2 and substantially corrects the ligand independent 
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growth observed in WT oncogene bearing HSC/Ps, very similar to the growth repression 
observed in the presence of EHop-016.   
Downstream from Rac, we show that Pak plays an essential role in KITD814V 
induced transformation. We utilized both an allosteric inhibitor of Pak, IPA-3, as well as 
a genetic approach to implicate Pak in KITD814V induced transformation. Although 
IPA-3 selectively inhibits the activation of Pak1 (171), at higher doses it has been shown 
to also inhibit the activation of other isoforms including Pak2 and Pak3 (171). Our 
studies utilizing a dominant negative form of Pak (K299R) confirmed IPA-3 findings 
demonstrating that Pak indeed contributes to KITD814V induced transformation; 
whether other isoforms of Pak also contribute to leukemogenesis remains to be 
determined. As animal models deficient in the expression of Pak isoforms become 
available, the role of specific isoforms of Pak in transformation can be more readily and 
efficiently addressed in future studies. Taken together, our studies identify a novel 
pathway involving Vav/Rac and Pak in regulating non-classical MPNs such as SM in 
which activating mutation of KIT plays an essential role. 
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CHAPTER FIVE 
SYNERGISTIC COOPERATION OF ONCOGENIC KIT IN CORE BINDING 
FACTOR (CBF) LEUKEMIAS 
 
5.A ABSTRACT 
12% of acute myeloid leukemia (AML) patients and 40% of patients with subtype 
M2 AML have the cytogenetic abnormality t(8; 21) (21). This chromosomal 
rearrangement generates the fusion protein AML1-ETO, leading to the disruption of the 
core binding factor complex that regulates the transcription of several genes in the 
hematopoietic stem and progenitor cells (32, 34, 185). AML patients harboring this 
translocation alone usually have a favorable prognosis; however, a substantial portion of 
patients bearing an additional oncogenic receptor tyrosine kinase, KIT, mutation have 
significantly worse prognosis (186, 187). A secondary mutagenic event of an activating 
mutation of aspartic acid to valine in the KIT receptor activation loop (KITD814V) 
which results in altered substrate recognition and utilization, constitutive tyrosine 
autophosphorylation, and promiscuous signaling. While clinical studies suggest poor 
prognosis due to the presence of both these mutations in AML patients; little however is 
known concerning the possible mechanisms of cooperation between AML1-ETO and 
KITD814V. In this study, we show that growth of AML1-ETO bearing myeloid cells 
remains ligand dependent, while myeloid cells that express both AML1-ETO and 
KITD814V demonstrate ligand independent proliferation. Furthermore, functional assays 
show that expression of AML1-ETO and KITD814V in the same cells results in 
increased cycling and decreased apoptosis, which may contribute to the observed ligand 
111 
 
independent proliferation. Interestingly, while the expression of KITD814V alone in 
myeloid cells results in significant activation of STAT3, STAT5, JAK2, Akt, and ERK 
MAPK pathway; the activation of these molecules is significantly dampened in the 
presence of AML1-ETO expression. To confirm that AML1-ETO alone is not sufficient 
to induce leukemia; but needs the presence of KITD814V, a syngeneic murine 
transduction/transplantation model for myeloproliferative neoplasm (MPN) was 
established. In vivo results demonstrated that mice transplanted with AML1-ETO and 
KITD814V bearing cells succumbed to a fatal MPN-like phenotype, while AML1-ETO 
expressing mice remained disease free. Although, no significant differences in the 
phenotypic manifestation was observed in cohorts of mice bearing KITD814V mutation 
alone or combination of both AML1-ETO and KITD814V (similar splenomegaly and 
hepatomegaly), there were significant differences in survival of the two groups of mice 
(median survival 23 days vs. 39 days, respectively). These studies suggest that the fusion 
protein AML1-ETO is not sufficient to induce ligand independent growth in vitro, nor 
MPN in vivo, but requires cooperation with a secondary mutagenic event, KITD814V, to 
promote leukemogenesis.   
  
5.B INTRODUCTION 
Acute myeloid leukemia is thought to occur as a result of cooperation between 
alterations in genes that encode for transcription factors and genes that regulate the 
growth and survival of hematopoietic cells (188). Genetic alterations in TFs constitute 
chromosomal translocations which inhibit the differentiation potential of hematopoietic 
progenitors. In contrast, alterations in genes involved in growth and survival of 
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hematopoietic progenitors include single point mutations in growth factor receptors or 
their downstream kinases (189-191). In general, leukemic clones only possesses a single 
chromosomal translocation in TFs. Likewise, leukemic cells in which more than one 
mutation in the receptor tyrosine kinases occur are also rare. However, there are several 
examples of leukemic clones in which both a chromosomal translocation in a TF can be 
found along with a point mutation in the receptor tyrosine kinase, such as KIT(192).  
The cooperative model of AML has been substantiated by a significant number of 
experimental models. For example, the fusion protein AML-1-ETO is one of the most 
frequently seen chromosomal translocation in patients with core binding factor acute 
myeloid leukemia (CBF-AML) (32, 193). However, in several murine models of 
leukemogenesis, the presence of AML-1-ETO in itself does not appear to be sufficient for 
disease development (194, 195). Under conditions when mice have been targeted to 
express AML1-ETO in hematopoietic cells; mice only develop a myeloproliferative 
neoplasm but never result in the development of AML (196). However, treating AML1-
ETO expressing mice with ethylnitrosourea (ENU) renders these mice susceptible to 
AML (197, 198). This data strongly support the hypothesis that mutations in TFs alone 
are not sufficient to develop leukemia. To this end, emerging clinical data suggests that 
the molecular events leading up to AML might involve activating mutations in the 
receptor tyrosine kinases including KIT (132, 199-201). Clinical reports strongly suggest 
cooperation between activating KIT mutations and core binding factor TFs in a subset of 
AMLs. Approximately 12.8 to 46.1% of adults with core binding factor leukemias 
express activating KIT mutations (29-31). Furthermore, 12% of pediatric non-acute pro-
myelocytic leukemia (APL) AML carry an activating mutations of KIT (31). Therefore, 
113 
 
determining the extent to which activating KIT mutations and CBF-TFs cooperate in 
AML and identifying the mechanism(s) by which they cooperate is critical to the 
development of targeted therapies for patients with this subset of AML.  
Of all AML patients, 15% express alterations in the core binding factor TFs. In 
general, the median age of these patients is significantly lower and their over prognosis is 
more favorable than AML patients with other chromosomal alterations (202-204). In 
contrast, a higher incidence of elevated WBC counts, greater relapse incidence (RI) and 
worse overall survival (OS) has been observed in AML patients co-expressing CBF TFs 
(AML1-ETO or CBF-MYH11) and KIT mutations (29-34, 205-208). Importantly, KIT 
mutations are not observed in other subsets of AML (32).  
Although these studies strongly support the notion of cooperation between KIT 
mutations and CBF-TFs in a subset of AML, and suggest that KIT mutations have a 
negative overall impact on the outcome of CBF-AML in both adult and pediatric patients, 
they do not directly prove the notion that KIT mutations cooperate with CBF TFs in 
CBF-AML. While correlations made in clinical studies suggest poor prognosis due to the 
presence of both these mutations in AML patients; little however is known concerning 
the possible mechanisms of cooperation between AML1-ETO and KITD814V.  
Expanding our understanding of the molecular pathogenesis of CBF-AML and associated 
mutations would open potential venues for possible therapeutic intervention. In this study 
we investigate the molecular mechanisms of growth and leukemic potential of activating 
KITD814V mutation and AML1-ETO. Our results suggests that the fusion protein 
AML1-ETO alone is insufficient to induce ligand independent growth in vitro, nor MPN 
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in vivo, but requires cooperation with a secondary mutagenic event, KITD814V, to 
promote leukemogenesis.  
 
5.C RESULTS 
Transforming potential of KITD814V and AML1-ETO in vitro 
Although there is a clinical association concerning AML patients that harbor both 
a CBF gene rearrangement and a KITD816V mutation, cooperation between the two 
genetic aberrations has not been established. To assess whether KITD814V bearing cells 
that co-express a CBF-translocation, either AML1-ETO or CBFß-MYH11 show an 
cooperation in growth, constructs expressing KITD814V and the CBF-translocations 
were first generated. To establish our cell lines, cDNAs encoding KITD814V was 
isolated from a bicistronic ecotropic retroviral, pMIEG3, vector expressing EGFP using 
restriction enzymes NotI and EcoR1. The KITD814V cDNA was then subcloned into a 
pMIEG3 vector expressing a human (h) CD4 tag, pMIEG3-hCD4. The core binding 
factor gene rearrangements were expressed in plasmids bearing an EGFP marker, 
pMIEG3-CBFß-MYH11-EGFP, and pMIGR1-AML1-ETO-EGFP (Figure 5.1.A).  
115 
 
 
Figure 5.1. A schematic diagram of retroviral constructs and analysis of KIT and 
AML1-ETO expression in myeloid cells. 
 
(A) MIEG3-based retroviral constructs used to express KITD814V, AML1-ETO and 
CBFβ-MYH11 with EGFP and human (h) CD4 markers. (B) Representative dot blots 
showing the expression of 32D cells bearing either pMIEG3-KITD814V-hCD4, or 
pMIGR1-AML1-ETO-GFP, CBFβ-MYH11 alone or in combination with KITD814V. 
Expression of hCD4 was determined by hCD4-phycoerythrin (PE) antibody and flow 
cytometric analysis. 
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Retroviral supernatants were prepared and 32D cells were stably infected with a single 
plasmid or a combination of activating KITD814V and a CBF translocation expressing  
plasmids. Cells were sorted by FACS to homogeneity based on the expression of EGFP, 
hCD4, or both (Figure 5.1.B).  
To determine the extent of ligand-independent proliferation of 32D cells 
harboring CBF translocations and KITD814V, cells were deprived of growth factors and 
cytokines for 8 hours prior to being cultured for 48 hours in a 96-well plate. When grown 
in the absence of growth factors AML1-ETO and CBF-MYH11 expressing cells 
demonstrated little growth, while cells bearing the KITD814V mutation grew in a ligand-
independent manner as previously described in this thesis. Cells harboring a core binding 
factor translocation, either AML1-ETO or CBF-MYH11, in the presence of KITD814V 
showed a significant increase in ligand-independent proliferation compared to cells 
bearing KITD814V alone (Figure 5.2). This significant increase in the proliferation of 
cells bearing both a CBF translocation and an acquired activating KIT mutation provides 
experimental support that cooperation exists between KITD814V and CBF fusion 
proteins. 
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Figure 5.2. Cells bearing KITD814V and CBF TFs cooperate to enhance growth. 
 
Proliferation was assessed by thymidine incorporation in 32D cells expressing 
KITD814V, AML1-ETO, AML1-ETO and KITD814V, CBF-MYH11, or CBF-
MYH11 and KITD814V in the absence of growth factors. Bars denote the mean 
thymidine incorporation (cpm ± SD) from one of three independent experiments 
performed in quadruplicate. *p-value<0.05, Cells co-expressing AML1-ETO or CBF-
MYH11 and KITD814V vs KITD814V expressing cells alone. 
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Cells expressing AML1-ETO and KITD814V exhibit an increase in cell cycle and 
survival 
We demonstrated that AML1-ETO and KITD814V co-expressing cells show 
increased proliferation. It has previously been reported that expression of the core 
binding factor transgene, AML1-ETO, in murine myeloid cells leads to an accumulation 
of cells in G1 phase (209, 210). To examine the effect of AML1-ETO expression on cell 
cycle regulation in KITD814V-expressing cells, we utilized a propidium iodide assay. 
32D cells bearing AML1-ETO and/or KITD814V, or WT KIT were starved of growth 
factors and serum for 6 hours. These cells were cultured in a 24-well plate (2x105 
cells/well) in replicates of four for up to forty-eight hours at 37°C. Cells were collected 
and DNA content was determined by staining the cells with propidium iodide and 
analyzed by flow cytometry. Consistent with prior studies, cells bearing AML1-ETO 
transcripts showed an increase in the accumulation of cells in G1 phase of cell cycle as 
compared to 32D cells bearing the wild type form of the KIT receptor (Figure 5.3.A). The 
percentage of AML1-ETO or WT KIT expressing cells in S-phase steadily decreased 
over 24 hours before undergoing quiescence (Figure 5.3.B). Notably, AML1-ETO with 
KITD814V bearing cells maintained a significantly increased percentage of cells in S-
phase as compared to KITD814V alone (Figures 5.3.B). To determine whether other 
functional phenotypic changes occurred, we performed an apoptosis assay in which cells 
were collected and stained with Annexin V-PE and 7-AAD and subjected to flow 
cytometry analysis (Figure 5.4.A). While cells bearing WT KIT or AML1-ETO had 
undergone complete apoptosis, there was a modest increase in survival of cells co-
expressing AML1-ETO and KITD814V compared to KITD814V alone (Figure 5.4.B). 
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These findings suggest that AML1-ETO is not sufficient to induce ligand-independent 
growth and proliferation of 32D cells in the absence of growth factors. However, 
KITD814V bearing cells exhibit a significant increase in ligand-independent growth in 
the presence of AML1-ETO, which is due to an increase of cells in S-phase and increased 
survival. 
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Figure 5.3. Cells bearing AML1-ETO and KITD814V show enhanced percentage of 
cells in S-phase of cell cycle relative to AML1-ETO and KITD814V expressing cells. 
 
WT KIT, KITD814V, AML1-ETO, and AML1-ETO and KITD814V expressing cells 
were grown under no growth factor conditions for 0, 12, 24 or 48 hours prior to being 
stained with propidium iodide and analyzed by flow cytometry. Cycling was determined 
by assessing cells in S-phase if cell cycle. A) Representative cell cycle data showing the 
total percentage of cells in S-phase. B) Line graph shows S-phase cycling at various time 
points in the absence of serum and cytokines. Bars denote the mean percentage of cells in 
S-phase (%± SD) from one of three independent experiments performed in quadruplicate. 
*p-value<0.05, KITD814V and/or AML1-ETO vs. WT KIT. **p-value<0.05, 
KITD814V and AML1-ETO co-expressing cells vs. KITD814V. 
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Figure 5.4. Survival of AML1-ETO and KITD814V expressing cells. 
 
WT KIT, KITD814V and/or AML1-ETO cells expressing cells were grown in no growth 
factor conditions for 0, 6, 12, 24 or 48 hours prior to being analyzed by flow cytometry 
after staining with Annexin V-phycoerythrin and 7-AAD. A) Representative dot blot 
showing the percent apoptosis. (B) Bars denote the mean percentage of Annexin V and 7-
AAD negative (viable) cells (mean % ± SD) from one of three independent experiments 
performed in quadruplicate. 
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To determine the extent of contribution that downstream pathways impart on 
AML1-ETO and KITD814V-mediated hyperproliferation, pharmacological inhibitors 
were used to assess sensitivity of these cells to inhibition of downstream pathways. As 
there was a significant decrease in KITD814V-induced constitutive activation of Jak2 in 
the presence of AML1-ETO, we examined if pharmacological inhibition of Jak2 would 
have a differential affect among the cell lines. Treatment of various cells with a JAK2 
inhibitor showed a dose-dependent reduction in ligand-independent hyperproliferation of 
KITD814V bearing cells, but only a modest reduction in proliferation other cell lines. 
Inhibition was more pronounced in KITD814V bearing cells than those expressing 
AML1-ETO and KITD814V (Figure 5.5.A). Furthermore inhibition of PI3K by, 
Ly294002, showed a dose-dependent response in to KITD814V bearing cells, and to cells 
co-expressing KITD814V and AML1-ETO at higher doses (Figure 5.5.B). While, in the 
presence of MEK inhibitor, PD98059, ligand-independent hyperproliferation of 
KITD814V-expressing cells was significantly reduced in AML1-ETO co-expressing cells 
compared to KITD814V only expressing cells (Figure.5.5.C).  These studies suggest that 
AML1-ETO cells co-expressing KITD814V may utilize signal transduction pathways 
that are different from those activated by KITD814V only expressing cells. 
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Figure 5.5. Differential effects of various inhibitors on the growth of KITD814V or 
KITD814V and AML1-ETO bearing cells. 
 
32D cells bearing WT KIT grown in the presence of IL-3 or KITD814V or KITD814V 
with AML1-ETO bearing cells grown in the absence of growth factors and (A) Jak2 
inhibitor, (B) PI3K inhibitor, Ly294002, or (C) MEK inhibitor, PD98059, were subjected 
to a [3H] thymidine incorporation assay. Bars represent mean cpm ± SD from 2 
independent experiments performed in replicates of four. *,p-value<0.05, 0µM vs. 
various drug concentrations. 
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Transplantation of mice with cells co-expressing AML1-ETO and KITD814V develop 
myeloproliferative neoplasms (MPN) 
Previous studies have shown that AML1-ETO does not promote leukemia in 
murine models without a secondary mutagenic event, yet the role of the secondary 
mutation by oncogenic KIT is poorly understood. To determine the extent to which 
AML1-ETO and KITD814V cooperate in the generation of a myeloproliferative 
neoplasm–like disease, we used a C3H/HeJ syngeneic murine model. Two weeks post-
transplantation of the C3H/HeJ mice with cells bearing KITD814V and AML1-ETO, 
mice were monitored for signs of leukemia development, including physical appearance 
and percentage of EGFP+ and/or hCD4+ cells in the peripheral blood. Thirty days after 
post-transplantation mice began to display symptoms of MPN including increase white 
blood cell counts and rapid decline in health. At signs of moribund, these mice were 
sacrificed. Splenomegaly and hepatomegaly was observed in every animal transplanted 
with cells bearing AML1-ETO and KITD814V (Figure 5.6.A and data not shown). We 
analyzed the percentage of transplanted cells via FACS analysis of EGFP+ and hCD4+ in 
peripheral blood, bone marrow, and spleen suspensions, and observed donor cells bearing 
AML1-ETO and KITD814V in all tissues (Figure 5.7). All recipients transplanted with 
AML1-ETO and KITD814V co-expressing cells succumbed to fatal MPN within 65 days 
of transplantation (Figure 5.6.B). In contrast, mice transplanted with WT KIT or AML1-
ETO alone did not show obvious signs of disease progression during the course of the 
study. We further confirmed engraftment of transplanted cells by western blot analysis in 
which lysates were prepared from harvested bone marrow and spleen cells in leukemic 
mice (data not shown). 
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Figure 5.6. AML1-ETO and KITD814V co-expressing cells confer a MPN 
phenotype in syngeneic murine transplantation model. 
 
 (A) Representative pictures of spleen from mice bearing WT KIT, KITD814V, or 
KITD814V and AML1-ETO. (B) Cumulative survival analysis using Kaplan-Meier log-
rank test of recipient mice bearing WT KIT (n=5), AML1-ETO (n=3), KITD814V (n=15) 
or AML1-ETO plus KITD814V (n=14) expressing 32D cells. 
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Figure 5.7. Engraftment of cells in KITD814V and/or AML1-ETO transplanted 
recipients. 
 
Representative engraftment flow cytometry dot plots of peripheral blood, bone marrow, 
and spleen cells demonstrating the presence of EGFP+ and hCD4+ of WT KIT, AML1-
ETO, KITD814V or AML1-ETO plus KITD814V transplanted mice upon sacrifice. 
 
Histological analysis of bone marrow from mice transplanted with WT KIT-
bearing cells showed normal marrow composition with a mixed population of immature 
myeloid and erythroid progenitors (Figure 5.8. Panel 1).  A distinct area of red pulp and 
white pulp that is indicative of normal spleen tissue was observed (Figure 5.8. Panel 2). 
Normal liver and healthy normal lung was observed in control mice or AML1-ETO mice 
(Figure 5.8. Panel 3 & Panel 4).  Tissues from mice transplanted with cells bearing a 
combination of AML1-ETO and KITD814V were hyperplastic with disruption of normal 
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tissue architecture in the bone marrow, spleen, liver and lung. Multiple mitotic events 
were observed in the bone marrow with the majority of marrow infiltrated with tumor 
cells and only a few normal myeloid and erythroid progenitors (Figure 5.8. Panel 1). The 
architecture of the spleen was disrupted by tumor cells with little red or white pulp. 
Again, many mitotic events were observed (Figure 5.8. Panel 2). Also, tumor cells were 
abundant in periportal area and in liver sinusoids (Figure 5.8. Panel 3).  Pulmonary 
vessels were filled with tumor emboli, resulting in widened alveolar septa including 
partial thickening of alveolar walls, accompanied by several mitotic events (Figure 5.8. 
Panel 4). 
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Figure 5.8. Histopathological analysis of mice transplanted with 32D cells expressing 
the indicated retroviral constructs. 
 
Bone marrow, spleen, liver, and lungs from the recipient mice upon sacrifice were fixed 
in 10% buffered formalin, sectioned, and stained with hematoxylin and eosin. 
Representative tissue from transplanted mice. Top panels are from representative WT 
KIT transplanted mice. Middle panels are from KITD814V transplanted mice. Bottom 
panels are from AML1-ETO plus KITD814V transplanted mice. Panel 1: Normal bone 
marrow with mixed population of immature myeloid and erythroid progenitors. Panel 2: 
Normal spleen with distinct red pulp and white pulp. Panel 3: Normal liver. Panel 4: 
Normal lung. Panel 5: Bone marrow hypercellular with tumor cells with scattered normal 
bone marrow cells and many mitotic figures (small arrows indicate individual cells 
undergoing mitosis). Panel 6: Normal splenic architecture disrupted and replaced with 
large number of tumor cell and many mitotic events. Panel 7: Large areas of liver 
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necrosis with surrounding tumor cells with many undergoing mitotic events (arrowheads 
indicate tumor cells circulating in blood vasculature). Panel 8: small venule with 
circulating tumor cells, partial thickening of alveolar walls with tumor cells and some 
mitotic events. Panel 9: Few normal erythroid and myeloid components replaced by 
tumor cells with some mitotic figures. Panel 10: Disruption of red and white pulp by 
large number of tumor cells, many undergoing mitotic events. Panel 11: Periportal area 
plus liver sinusoids filled with tumor cells. Panel 12: Pulmonary vessel filled with tumor 
emboli, resulting in widened alveolar septa. Partial thickening of alveolar walls with 
tumor cells, several mitotic events. Bar: 100 μM. Similar results were seen in several 
tissue sections from other transplanted mice. 
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5.E CONCLUSIONS 
Clinical reports have suggested a strong association between CBF-AML and the 
presence of activating KIT mutations in up 50% of AML cases. In patients in which 
KITD816V is present along with the fusion proteins AML1-ETO or CBFβ-MYH11; 
these patients present with poor overall prognosis and overall survival. Although 
KITD816V mutations confer a poor prognosis to AML1-ETO or CBFβ-MYH11 bearing 
patients, at this time there is no direct evidence as to how these two mutations may 
possibly cooperate. 
Our results show that cells bearing a CBF translocation, AML1-ETO or CBFβ-
MYH11, and KITD814V, demonstrate a significant increase in ligand independent 
proliferation compared to KITD814V bearing cells alone. Growth of cells bearing WT 
KIT, AML1-ETO, or CBFβ-MYH11 remains ligand dependent. Furthermore, cells co-
expressing AML1-ETO and KITD814V demonstrate an increase in cell cycle and a 
decrease in apoptosis, suggesting that the enhanced proliferation of these cells may be 
due to increased cell cycle and increased survival. Inhibitor studies demonstrated that 
signaling between KITD814V bearing cells alone and those bearing the two mutations, 
AML1-ETO and KITD814V, may be unique, as Jak and PI3K inhibition preferentially 
leads to a significant decrease in the growth of KITD814V bearing cells as compared to 
KITD814V and AML1-ETO co-expressing cells.  
In vivo, we transplanted cohorts of animals with cells bearing KITD814V, which 
developed MPN by median day 23, while cohorts co-expressing AML1-ETO and 
KITD814V showed a delayed latency with median MPN development at day 39. 
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Although in vitro studies showed an increase in the proliferation in cells co-expressing 
the two mutations, the in vivo delay in survival of mice bearing the two mutations may be 
due to several factors.  32D cells may not be capable of differentiating abnormally when 
expressing KITD814V and AML1-ETO together. Also, the presence of AML1-ETO may 
result in poor engraftment or homing of these cells. 
Overall, our results support the hypothesis that AML1-ETO and KITD814V 
interact in a cooperative manner, resulting in increased growth and survival in vitro and 
development of MPN in vivo. Also our study shows differential signaling pathways 
utilized by cells expressing KITD814V and AML1-ETO. In summary, AML involving 
CBF TFs, and KIT may utilize a distinct strategy from patients with SM bearing 
activating KIT mutations alone. 
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CHAPTER SIX 
GENERATION OF HUMAN XENOGRAFT MODELS TO STUDY THE 
DEVELOPMENT AND PROGRESSION OF MASTOCYTOSIS AND ACUTE 
MYELOID LEUKEMIA 
 
6.A INTRODUCTION 
Acute myeloid leukemia (AML) is a devastating disease predominantly affecting 
elderly individuals and accounts for about 25% of all leukemia in adults in the western 
world (211, 212).  Patients with AML often present with an overabundance of myeloid 
cells, anemia, and thrombocytopenia.  Furthermore, patients under 65 years of age 
demonstrate a 34.4% 5-year survival rate, while the outlook for patients over 65 years of 
age is a dismal survival rate of 4.3% (211). It is extremely important to recognize the 
difficulty in treating older patients with AML.  As patients age, they tend to develop 
multiple co-morbidities and, thus, become less tolerant of harsh chemotherapy and 
radiation (211-213).  Because of these complications, older patients are often ineligible 
for cytotoxic therapy and are only treated with supportive, rather than curative care.  
Therefore, it is imperative that therapies with reduced toxicity and increased efficacy are 
developed to treat AML patients. Internal tandem duplications in FMS-like tyrosine 
kinase (FLT3-ITD) are insertions of several amino acids into or around the 
juxtamembrane domain and are found in approximately 20-25% of all AML patients, 
usually as an isolated anomaly (214-218). The presence of FLT3-ITDs contributes to an 
unfavorable prognosis. Despite promising in vitro studies using FLT3 inhibitors, such as 
PKC412, SU5614, and sorafenib, the clinical response of AML patients with FLT3-ITD 
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are moderate and temporary (88, 219). Thus, targeting FLT3-ITD in AML is a reasonable 
approach. 
Systemic mastocytosis (SM) is a hematological neoplasm characterized by the 
abnormal deposition and accumulation of mast cells in various organs including skin, 
bone marrow and visceral organs (38, 39). A somatic point mutation has been identifies 
after genetic sequencing in the receptor tyrosine kinase, KIT, at codon 816 and plays a 
critical role in the pathogenesis and diagnosis of SM as it’s detectable in >90% of SM 
patients (220). Along with KIT mutations patients with more aggressive SM frequently 
have mutations in genes such as TET2, SRSF2, ASXL1, RUNX1, and CBL that may 
contribute to the SM (51). KITD816V has also been observed in a subset of CBF-AMLs, 
resulting in overall poor prognosis. As of yet there are no clinically efficacious therapies 
for malignancies harboring an activating KITD816V mutation.  
Over the years, numerous transgenic murine models have been designed to 
investigate target molecules that are involved in AML and SM as well as the response of 
these targets to therapeutic inhibition. These models have provided valuable insight into 
the mechanisms and targets of therapeutic intervention. However, the only way to know 
whether a patient’s leukemia will respond to a similar therapeutic regime, one must 
examine the response of that human leukemia. A model examining the response of these 
factors in human neoplasms, rather than a murine neoplasm, would provide clinically 
relevant model of disease and therapeutic treatment. The most biologically relevant 
model is the in vivo use of human xenografts of hematological malignancies in 
humanized murine models. 
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Over the past two decades, the humanized murine models have been utilized and 
refined allowing for the transplantation of human hematopoietic cells into recipient 
animals without graft rejection (221). Generation of a NOD/SCID model has allowed for 
leukemic cell lines and primary patient samples to be engrafted and resemble the 
distribution and course of the human disease (222). Further refinement of the strain 
through defects of the interleukin-2 receptor gamma chain [NOD/SCID IL2Rnull (NSG)] 
further impaired the murine immune system by depleting innate immunity and natural 
killer (NK) cell activity leading to better engraftment and differentiation of transplanted 
human hematopoietic stem cells (115, 223). Additional improvements have been made on 
this model in which transgenic expression of human stem cell factor hSCF, hGM-CSF, 
and hIL-3 in the NSG background led to improvements in engraftment of AML samples 
and pre-leukemia modeling (116).  
While investigators are beginning to use these models by developing them at their 
respective institutions; there is significant amount of variability in the engraftment of 
studies have been described so far (Figure 6.1). Furthermore, no xenograft models of 
human MPNs have been described. These models thus have to be generated 
independently in one’s own institutions before detailed additional studies can be pursued. 
The purpose of these studies was to utilize NOD/SCID, NSG and NSG with human 
cytokine mice to establish murine xenograft models of human hematologic malignancies 
including AML and SM. 
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Figure 6.1. Factors affecting leukemia xenograft engraftment, growth and outcome. 
Adapted from Meyer and Debatin (224). 
 
 
 
 
 
 
 
 
 
 
 
Transplant source
Preprocessing
Transplant procedure
Conditioning General
Estimation of 
engraftment
Recipient characteristics/
Strain specific
• Patient sample
• at diagnosis
• at relapse
• Direct transplant
• Shipping
• Cryopreservation
• Cell sort
• Systemic (i.v.)
• Locally (s.c., i.p.)
• dose/number
• Irradiation
• NK cell depletion
• NOD/SCID
• NSG
• NSG+cytokines
• Age
• Gender
• Clinical signs
• Overt leukemia
• Observation time
136 
 
6.B RESULTS 
Pharmacological inhibition of focal adhesion kinase (Fak) and p21-activated kinase 
(Pak) represses growth of FLT3-ITD positive patient derived cells in NSG mice 
Our lab has recently shown that focal adhesion kinase (Fak) and p21-activated 
kinase (Pak) to be constitutively active downstream effectors of FLT3-ITDs. Inhibition of 
these effectors represses the growth of murine leukemic cells in vivo and primary AML 
cells in vitro (225). However, the impact of inhibition of these molecules in vivo on 
human leukemia cell has not been investigated. We investigated whether inhibition of 
downstream effectors of FLT3-ITD, Fak and Pak, can suppress engraftment of patient-
derived MV4;11 cells bearing FLT3-ITD in vivo. 
Engraftment and growth capabilities of a patient-derived MV4;11 cells was 
investigated using an immunodeficient xenograft model. Six-week old non-obese diabetic 
severe combined immunodeficient gamma (NSG) (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) 
recipient mice were sub-lethally irradiated (300 rad) and intravenously (i.v.) injected with 
1x107 MV4;11 cells. Drug treatments were initiated 14 days post-transplantation. 
Recipient mice were divided into multiple groups including vehicle (10% DMSO in PBS, 
n=3), Fak inhibitor (F-14, 20mg/kg/day in vehicle, n=3), and Pak inhibitor (PF-3758309, 
25mg/kg/day in vehicle, n=3) groups. The mice received intraperitoneal (i.p.) injections 
of the above drugs for five consecutive days. Treated mice were harvested at day 30 post-
transplantation. Engraftment of MV4;11 cells in the bone marrow was assessed by 
analyzing the expression of human (h) CD4 expression by flow cytometry (Figure 6.2.A). 
Previous studies have shown the expression of hCD4 antigen on MV4;11 cells (226). In 
vivo transplantation of FLT3-ITD bearing patient-derived MV4;11 cells resulted in 
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leukemogenesis as characterized by splenomegaly and hepatomegaly (Figure 6.2.C). 
Importantly, treatment with F-14 or PF-3758309 showed a reduced presence of hCD4 
positive cells in the bone marrow compared vehicle-treated controls (5.51% and 4.68% to 
27.4% respectively) (Figure 6.2.B). While vehicle-treated mice exhibited splenomegaly, 
this was significantly decreased in F-14 and PF-3758309-treated mice (Figure 6.2.C). 
These findings indicate that AML patient-derived cells can be successfully transplanted 
into NSG mice and that they respond to FAK and Pak inhibitors in vivo by repressing the 
presence of leukemic cells.   
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Figure 6.2. Impact of FAK and PAK inhibition on MV4;11 cell engraftment. 
 
 (A) Representative flow cytometry staining for human CD4 positive MV4;11 cells 
vehicle, FAK inhibitor (F-14) and PAK inhibitor (PF-3758309) treated recipients, 
respectively. (B) Mean human CD4 positive cells in bone marrow. (C) Quantitative 
differences in spleen mass of vehicle, F-14 or PF-3758309 treated cohorts. *p-value<0.05 
vehicle vs F-14 or PF-3758309 (n=3 mice per cohort). 
 
Subcutaneous growth of human systemic mastocytosis patient-derived KITD816V 
bearing cells  
We next generated a murine model of human SM. Although oncogenic KIT is 
present in a vast majority of systemic mastocytosis patients, development and severity of 
the disease may be affected by additional mutations. In this regard TET2, a tumor 
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suppressor that has an enzymatic function in DNA demethylation may contribute 
significantly to SM (52, 53).  
To investigate the cooperative effects of loss of TET2 in the presence of 
oncogenic KIT, we transplanted systemic mastocytosis patient derived cells, HMC1.2, 
bearing KITD816V in the presence or absence ofTET2 using a plasmid bearing a hTET2 
shRNA. Two cohorts in which 1x107 HMC1.2 cells alone or HMC1.2 cells expressing 
hTET2 shRNA were transplanted subcutaneously into the right flank of non-obese 
diabetic severe combined immunodeficient (NOD/SCID) recipient mice. Tumor growth 
was monitored by external caliperation in which tumor volume [Tumor volume=1/2 
(length x width2)] was monitored following six weeks of transplantation. Mice were 
harvested at week 10 post-xenotransplantation and tumor growth was assessed.  Tumor 
growth and mass were significantly enhanced in mice bearing HMC1.2 cells with shRNA 
TET2 suppression relative to HMC1.2 cells (Figure 6.3.A and 6.3.B). Representative 
pictures of each cohort are shown in Figure 6.3.C. These results suggest that loss of Tet2 
in conjunction with the presence of KITD814V mutation enhances the tumorigenic 
potential of these cells. 
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Figure 6.3. HMC1.2 cells with or without hTET2 shRNA expression 
subcutaneously were injected in the right flank of NOD/SCID mice. 
(A) Tumor mass following sacrifice of recipient animals at 10 weeks post-
transplantation. *p-value<0.05, HMC1.2 vs. HMC1.2 with hTET2 shRNA. n=5 mice 
(B) External caliperation measurements of tumor growth determined by volume. *p-
value<0.05, HMC1.2 vs. HMC1.2 with hTET2 shRNA. n=5 mice (C) Representative 
images of tumor volume in HMC1.2 cells bearing NOD/SCID and HMC1.2 cells 
expressing hTET2 shRNA. 
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NSG and NSG plus cytokine mice show engraftment of primary AML patient-derived 
cells 
We obtained five frozen AML patient samples with >75% leukemic blasts from 
Cleveland Clinic (Cleveland, OH). NSG and NSG with cytokine recipient mice were sub-
lethally irradiated (300 rad) 24 hours prior to transplantation. Patient samples were 
thawed and viability was assessed by trypan blue staining and viable cells were counted. 
A small sample of cells from each vial was subjected to flow cytometry to assess the 
overall content of hCD33 and hCD45 positive cells. Recipient mice were transplanted 
intravenously with 1.8-5x106 hCD33+/hCD45+ mononuclear cells. Two patient samples, 
Patient 12111502 and 13051501, were transplanted into NSG recipient animals that 
expressed hSCF, hGM-CSF, and hIL-3, and three patient samples (Patient 13071701, 
13040401, and 12111501) were transplanted into NSG recipient mice (Table 6.1).  To 
determine the engraftment efficiency of these cells, quantitative analysis of peripheral 
blood, bone marrow, and spleen was performed at time of harvest.  Engraftment of 
human AML patient-derived cells was determined as the percentage of cells expressing 
hCD45+hCD33+ (Figure 6.4.B). Mean engraftment percentages in the peripheral blood, 
bone marrow and spleen from five mice injected with cells derived from Patient 
13051501 showed significant levels of engraftment in NSG mice bearing human 
cytokines (Figure 6.4.C).  
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Figure 6.4. Engraftment of AML-derived patient 13051501 cells. 
 
 (A) Mean ± SD of human CD33 and human CD45-positive engrafted cells in peripheral 
blood, bone marrow, and spleen. (B) Representative hCD45+/CD33+ dot blots of 
peripheral blood, bone marrow and spleen from patient 13051501-transplanted NSG with 
human cytokine mice. 
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AML patient samples
Case ID Specimen MNC sent Description Institution Murine recipient
12111502 75340.0.10 20 million/vial 78% blasts Cleveland Clinic NSG+cytokines
13051501 86380.1.10 20 million/vial 78% blasts Cleveland Clinic NSG+cytokines
13071701 88640.2.9 20 million/vial 78% blasts Cleveland Clinic NSG
13040401 82960.1.10 30 million/vial 78% blasts Cleveland Clinic NSG
12111501 75320.1.6 16.5 million/vial 78% blasts Cleveland Clinic NSG
Table 6.1. Primary AML patient-derived samples for xenograft transplantation in 
NSG or NSG with cytokines sublethally irradiated recipient hosts. 
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6.C CONCLUSIONS 
Our data suggests a significant reduction in the leukemic burden of mice treated 
with Fak or Pak inhibition. Likewise, we demonstrate that loss of TET2 contributes to an 
aggressive tumor growth in human mast cell leukemic line harboring a KITD814V 
mutation. Although the mechanism by which TET2 mutation contributes to this 
aggressive growth is poorly understood, this observation is likely to be instrumental in 
designing novel therapeutic strategies for SM patients that bear both of these mutations. 
In the present study, we have used external measurements with calipers to 
establish tumor size, which can be a subjective. In the future, we intend to follow tumor 
progression through bioluminescent imaging to more accurately analyze the tumor 
volume and response to therapy. These studies have since been initiated and involve 
HMC1.2 cells bearing a firefly luciferase reporter transplanted into NOD/SCID recipient 
mice. In collaboration with Paul Territo, M.D. at the Office of Research Imaging at 
IUSM, tumor growth will be imaged following luciferin dosing.  In this manner, a tumor 
regression model can be established in which tumors can be grown to baseline volumes 
prior to therapeutic treatments, and growth or repression of the tumors can be accurately 
assessed. 
In addition to the above described models, we also demonstrate engraftment of 
primary human patient AML samples in NSG mice expressing human cytokines. While 
these studies are somewhat preliminary our results indicate great potential in 
understanding and treating AML utilizing these models. Some benefits include clinical 
manifestation of the disease in peripheral blood, bone marrow and spleen with minimal 
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variance from animal to animal with the same patient samples, which provides an ideal 
model for therapeutic regimes in the future.  
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CHAPTER SEVEN 
DISCUSSION 
 
Despite efforts to develop efficacious treatments and therapies for CBF-AML and 
SM patients bearing KITD816V mutations, current treatment options are limited and at 
best modestly effective. While AML patients harboring a CBF translocation have 
relatively successful treatment and positive prognosis, those patients harboring an 
additional mutation of an oncogenic KIT have a worse overall outcome (29, 30, 34). The 
significance of our studies is derived from the realization that despite the success of 
therapies such as imatinib, sunitinib, and dasatinib, for treating activating KIT induced 
GISTs; activation loop mutations of KIT are largely resistant to such available therapies. 
Further, the aberrant molecular mechanisms that regulate transformation in vivo via this 
mutation are poorly understood. Therefore, the overall goal of this project was to define 
the molecular mechanism(s) underlying the transformation capacity of KITD814V in 
HSC/Ps, with the long-term goal of defining novel therapeutic targets in CBF-AML and 
SM.  
As previously described, KIT encodes a receptor tyrosine kinase characterized by 
the presence of five Ig-like repeats in the extracellular domain and an insert that splits the 
cytoplasmic kinase domain into the triphosphate (ATP)-binding and phosphotransferase 
domain (67). The binding of SCF promotes dimerization of wild type KIT receptor and 
activates intrinsic protein kinase activity, resulting in transphosphorylation at critical 
tyrosine residues (67). In contrast, activation loop mutations of KIT (e.g. KITD816V in 
humans, KITD814V in mice) do not result in dimerization, but are found to result in 
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receptor self-association in the cytoplasmic region in absence of ligand stimulation. 
Although it is unclear how KITD814V undergoes self-association, rather than receptor 
dimerization; it has been hypothesized that KITD814V may stabilize a conformation 
equivalent to that induced by ligand binding to the wild type receptor. Therefore, 
KITD814V may not require its extracellular domain for constitutive activation and 
growth promoting signals. To examine this, we developed a chimeric KITD814V 
receptor in which the extracellular domain of the murine KIT receptor was replaced by 
the extracellular domain of the human macrophage colony-stimulating receptor. We were 
able to demonstrate that an acquired KITD814V mutation was sufficient to induce ligand 
independent growth and cellular hyperproliferation. By replacing the extracellular 
domain of KIT, the chimeric receptor is impervious to endogenous murine cytokine 
binding and stimulation. Our findings show that a KITD814V receptor devoid of its 
extracellular domain is constitutively activated and capable of ligand-independent growth 
and sufficient to induce MPN in vivo. Therefore it is possible that self-association of 
KITD814V may result from the D814V mutation itself and that the D814V mutation may 
activate KIT signaling by creating a novel receptor that is not reliant on the extracellular 
domain.  
Although a significant advance has been made in our understanding of the 
KITD814V receptor at the structural level; little is known about the aberrant signals that 
contribute to transformation by this mutation. To identify signaling pathways that are 
involved in KITD814V-induced MPN, we used a chimeric model to examine the role of 
seven specific intracellular tyrosine residues in KITD814V-induced MPN. Our findings 
show that intracellular tyrosine residues are important for KITD814V-induced MPN, 
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albeit to different degrees. Using 32D cells expressing CHRKITD814V or CHRD814V-
F7 cells we show that by mutating the tyrosine residues within the JM and/or kinase 
insert domain of KITD814V completely abrogates ligand-independent growth and 
transformation in vivo. Additionally our studies suggest that the signals initiated from 
tyrosine 719 appear to sufficiently contribute to KITD814V ligand independent growth in 
vitro, transformation in vivo, and activation of AKT, ERK, STAT5 and anti-apoptosis 
proteins Bcl-x and Bcl-2 to a similar extent as CHRD814V receptor. To a lesser extent, 
signals initiated from tyrosines 567, 569, 702, 728, or 934 appear contribute to 
KITD814V induced transformation.  Our findings suggest that tyrosine 719 has a 
dominant role in regulating KITD814V-induced MPN, and that downstream signaling 
pathways from tyrosine 719 are crucial for KITD814V pathology.  
Additional studies suggest that persistent activation of PI3K is observed in 
hematological malignancies and are necessary for KITD814V-induced transformation 
(133, 150). We show that tyrosine 719 is necessary for the p85 regulatory subunit of 
PI3K to bind to KITD814V.  Evidence suggests that PI3K activates GEF Vav that 
facilitates the conversion of Rac GTPases from an inactive GDP bound state to an active 
GTP bound state (72, 96, 97). Therefore we hypothesized that the hematopoietic specific 
GEF, Vav1, contributes to KITD814V induced transformation. Using 32D cells 
expressing WT KIT or KITD814V, we demonstrated constitutive hyperactivation of 
Vav1. To examine the relevance of Vav1 in meditating oncogenic KIT-induced ligand 
independent growth. We examined the effect of genetic disruption of Vav1 on the 
proliferative capacity of HSC/Ps expressing KITD814V. Comparing wild type or Vav1 
deficient primary murine bone marrow LDMNCs transduced with WT KIT or 
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KITD814V, we showed loss of Vav1 corrected ligand-independent hyperproliferation of 
KITD814V by 70%. As only modest reduction in growth was observed in Vav2 or Vav3 
null LDMNCs, this suggests that KITD814V signaling occurs through the hematopoietic-
specific expressed Vav1 rather than the other Vav family members. These findings 
suggest that ligand independent growth observed in LDMNCS expressing KITD814V is 
preferentially dependent on Vav1 since deficiency of Vav1 almost completely rescues 
this response. Furthermore, using an in vivo model, we found that loss of Vav1 in bone 
marrow of KITD814V transplant recipients resulted in a prolonged survival of leukemic 
mice. These observations validate the hypothesis that Vav1 contributes to KITD814V 
transformation.  
Since Vav1 is a critical GEF for Rho GTPases in particular Rac family of Rho 
GTPases, we examined whether Rac GTPases are also constitutively activated in cells 
expressing KITD814V. We demonstrated that activation of all Rac GTPases isoforms in 
the presence of KITD814V-expressing LDMNCs were dependent of Vav1 expression. To 
test the role of Rac GTPase activation on KITD814V-induce ligand independent growth 
and transformation dominant negative form of Rac was used and demonstrated 
significant rescue of ligand-independent hyperproliferation and MPN in a syngeneic 
transplantation model. The involvement of individual Rac isoforms was determined using 
primary murine cells with loss of Rac2, Rac1 (polyI:polyC-treated Rac1flox/flox;Mx1-Cre+) 
or both.  Both in vitro and in vivo studies suggest that both Rac1 and Rac2 are involved in 
KITD814V-induced transformation. Loss of both resulted in rescue of KITD814V-
induced hyperproliferation and transplanted recipients had prolonged survival, while loss 
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of individual Rac GTPase isoforms modestly, yet significantly abrogated 
hyperproliferation of KITD814V bearing cells. 
Given the involvement of Rac GTPases in transformation, we used a first 
generation small molecule inhibitor that inhibits the activation or Rac2. The drug 
NSC23766 suppresses the activation of GEF Trio and Tiam1 induced cell transformation. 
In human prostate cancer cell line, NSC23766 suppresses endogenous Rac1 activity and 
inhibits the proliferation, anchorage independent growth and invasion phenotypes that are 
Rac1 dependent. NSC23766 was subsequently shown to function by inhibiting Rac 
protein binding and activation by Rac specific GEF Trio and Tiam1 in a dose-dependent 
manner. Thus NSC23766 was initially thought to be a Rac-specific small molecule 
inhibitor that is capable of reversing cancer cell growth associated with Rac 
dysregulation. Although promising in regard to inhibiting the activation of Trio and 
Tiam1, our results using NSC23766 in murine 32D and p815 cell lines expressing 
KITD814V and Kasumi-1 cell lines expressing AML1-ETO and KITD816V 
demonstrated only a modest reduction in ligand independent growth. Furthermore, the 
inhibition in growth was observed at very high doses of NSC23766. Thus, although we 
have established that the Rac inhibitor NSC23766 (specific for GEF Trio and Tiam1) 
modestly inhibits KITD814V induced ligand independent growth in vitro, its utility as a 
drug for treating hematological malignancies involving KITD814V is likely to be limited 
due in part to low expression of Trio and Tiam1 in hematopoietic cells and in part due to 
this drug’s high IC50. So although a useful drug to establish proof of principal, additional 
Rac specific drugs that inhibit binding between hematopoietic specific GEF Vav1 and 
Rac would be beneficial. We then used a newly described Rac inhibitor, EHop-016, 
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which is a NSC23766 analog (157). EHop-016 functions by binding to Rac GTPases and 
inhibiting interactions between Rac GTPases and GEFs Vav. Indeed upon treatment with 
EHop-016, Vav1 binding with Rac1 was interrupted in KITD814V-expressing cells. 
EHop-016 also inhibited growth of cells bearing KITD814V 100-fold more effectively 
than the parental compound.  This further validates the hypothesis that GEF Vav1 and its 
downstream effectors, Rac GTPases, contribute to KITD814V induced transformation.  
In targeting Vav1 and Rac GTPases we further identified Pak as a downstream 
effector of Rac GTPases that is involved in KITD814V-induced transformation. 
Dominant negative and pharmacological approaches were used to assess the role of Pak 
in KITD814V induced transformation. In 32D cells, we observed that dominant negative 
suppression of Pak abrogated KITD814V-induced hyperproliferation. In targeting Pak 
pharmacologically with Pak inhibitor, IPA-3, we were able to demonstrate that inhibition 
of PAK activity in cells expressing KITD814V or KITD816V resulted in a dose-
dependent and statistically significant reduction in hyperproliferation.  Under no growth 
factor conditions cells expressing KITD814V had an increase in apoptosis upon IPA-3 
treatment compared to untreated KITD814V bearing cells. Syngeneic KITD814V 
transplant recipients succumbed to fatal KITD814V-induced malignancies by day 15 
post-transplantation, while mice bearing dominant negative PakK299R in the presence of 
KITD814V had a significantly delayed latency compared to KITD814V alone.  This data 
suggests that Pak inhibition in vitro with dominant negative suppression of Pak or 
pharmacological inhibition by IPA-3 successfully inhibited KITD814V and KITD816V-
induced hyperproliferation. Our in vivo data supports that suppression Pak delays 
KITD814V-induced MPN onset.  
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While these in vitro and in vivo data are informative, we further tested the 
potential of pharmacological suppression of Rac GTPases or Pak in activated KIT 
bearing human neoplasms. We cultured patient-derived SM cells bearing either wild type 
form of KIT or with an activating KITD814V mutation with EHop-016 or IPA-3. We 
observed a significant dose-dependent response to EHop-016 and IPA-3 in patient-
derived SM cells bearing KITD816V, but no significant response in those SM patient 
samples bearing wild type KIT. These data suggest that targeting Rac GTPases and Pak 
may have potential therapeutic benefits in treatment of KITD816V-bearing AML and 
SM. 
 
Significance 
Oncogenic mutations of the receptor tyrosine kinase, KIT, are associated with 
poor prognosis in human neoplasms. However, the molecular mechanism by which an 
activating KIT mutation acts to induce leukemogenesis is poorly understood. We 
discovered several novel findings regarding the molecular mechanisms of KITD814V-
induced malignancies. In the process of understanding these molecular mechanisms, we 
observed that intracellular tyrosines are crucial for ligand independent growth and MPN 
development. Specifically, signaling through tyrosine 719 was sufficient in itself to 
induce MPN. Furthermore, activation of PI3K through tyrosine 719 is critical for 
KITD814V-induced proliferation, activation of its downstream effectors Vav1, Rac 
GTPases and Pak, and for the development and progression of KITD814V-induced MPN 
in vivo. Collectively we demonstrated the novel role of Rac GTPases and Pak in 
activating KIT mutation induced neoplasms and show convincing evidence that targeting 
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Rac GTPases and Pak may provide therapeutic benefit to treat KITD816V-induced AML 
and SM. 
Drug development that targets KIT and its downstream effectors are suitable 
therapeutic targets, as KIT contributes to the initiation and progression of many human 
malignancies. Dysregulation of KIT through the mutation D816V is a common molecular 
aberration observed in advanced SM and CBF-AML patients with poor prognosis. The 
propensity of such human malignancies to be resistant to tyrosine kinase inhibitors 
emphasizes the importance of a deeper understanding of KIT signaling in cells expressing 
oncogenic mutants of KIT. With this knowledge novel target molecules for 
pharmacological intervention, such as Rac GTPases and Pak, can be discovered and 
novel therapeutic modalities can be developed. If the specific pathways that are utilized 
by the oncogenic mutants of KIT can be targeted, the risk of side effects should be 
reduced. It is also likely that simultaneously targeting different signaling molecules will 
circumvent the resistance to tyrosine kinase inhibitors. In many human malignancies 
multiple molecular aberrations can be observed. In CBF-AML, chromosomal 
rearrangements resulting in AML1-ETO or CBF-MYH11 result in a block of 
differentiation by acting in a dominant negative manner blocking transcription of genes 
important for hematopoietic differentiation. Advanced systemic mastocytosis patients 
have also been observed to also have mutations in genes that affect epigenetic regulation, 
such as TET2, ASXL1, and DNMT3A. As these diseases result from complex molecular 
aberrations having combinational therapies that target the effects of these multiple 
mutations may be necessary to demonstrate sustained activity. Therefore, furthering our 
understanding of the molecular mechanisms of oncogenic KIT mutations are of the 
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upmost importance and will translate into major advances on the treatment of SM and 
CBF-AML. 
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